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Neuroinflammation  
 
Neuroinflammation is a reaction of the brain to an undesirable stimulus. It occurs in many 
diseases, such as Alzheimer's disease (AD), Parkinson's disease, amyotrophic lateral sclerosis 
and multiple sclerosis. It can be initiated by pathogen-associated molecular patterns (stranger 
signals) as well as endogenously derived molecules such as those released from necrotic cells 
(danger signals). These molecules are detected by a host of receptors. In turn, these receptors 
activate signal transduction pathways regulating transcriptional and posttranscriptional 
processes. These lead to regulation of hundreds of genes, depending on the activated target 
cell. In order for the immune system to respond effectively, the initial signal must be 
amplified to recruit additional cells to the site of infection, induce antimicrobial activities and 
initiate adaptive immunity. Among the upregulated genes are cytokines, amplifying the 
inflammatory response, and chemokines, responsible for recruitment of additional immune 
cells. In addition, genes that encode proteins with antimicrobial activities are induced, as are 
genes that regulate substrate metabolism, protein synthesis, cell motility, phagocytosis and 
intracellular killing. Inflammatory responses are typically localized and involve 
communication between immune, vascular and parenchymal cells. Due to the blood brain 
barrier, circulating macrophages normally cannot enter the brain. Microglia, the brain’s 
resident macrophages, appear to be important sensors of initiating signals. When activated, 
they secrete inflammatory mediators that may act on astrocytes in order to induce secondary 
inflammatory responses (Glass et al., 2010). 
 
 
The translocator protein 
 
The translocator protein is one of the receptors that are upregulated under inflammatory 
conditions. In regions of focal cortical ischemia, a strong increase in the expression of this 
receptor has been observed (Dubois et al., 1988). This can be attributed to infiltrating 
macrophages, on which the receptor is abundantly present. Increased translocator protein 
expression also occurs in the presence of an intact blood brain barrier, when infiltrating 
macrophages are not present. Using autoradiography and the ligand PK11195 that binds to 
the translocator protein, it has been shown that under these circumstances increased 
expression occurs locally at activated microglia. Interestingly, microglia activation occurred 
retrogradely to the lesion causing the inflammation (Banati et al., 1997). Expression of the 
translocator protein is thus a marker of microglial activation and consequently of 
neuroinflammation in areas of subtle brain pathology and this can be used to monitor disease 
progress. In older literature, the translocator protein is also referred to as the peripheral 
benzodiazepine receptor or the omega-3 receptor (Papadopoulos et al., 2006). 
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PK11195 
 
The previously mentioned ligand PK11195 has been used extensively to determine 
translocator protein distributions. Its official name is [1-(2-chlorophenyl)-N-methyl-N-(1-
methylpropyl)]-3-isoquinoline carboxamide. Originally discovered as a displacement for 
diazepam, its displacement behavior compared with other ligands led to the conclusion that 
PK11195 binds to the translocator protein (LeFur et al., 1983a, 1983b). PK11195 labeled 
with radioactive hydrogen ([3H]PK11195) has been used extensively for autoradiography 
studies, mainly in brain research (Banati et al., 1997, 2000, Giannaccini et al., 2000, 
Campioni et al., 1998). Two enantiomers of PK11195 exist, with the right-handed enantiomer 
(R)-PK11195 showing higher uptake than the left-handed one (Shah et al., 1994). 
 
 
Positron emission tomography 
 
PK11195 can be labeled with the positron emitting radionuclide 11C, resulting in 
[11C]PK11195. This makes it possible to retrieve information about its distribution in vivo 
using positron emission tomography (PET). A PET scanner provides images of the three-
dimensional distribution of a (positron emitting) radionuclide (in this case 11C) by detecting 
the products of its radioactive decay. In this decay process, a positron is emitted, which, after 
traveling a small distance in tissue, combines with an electron. In the subsequent annihilation 
process, positron and electron are converted into two photons of 511 keV that are emitted in 
essentially opposite directions. PET is based on the coincidence detections of these two 
photons. By detecting a large number of these coincidence events, a three-dimensional image 
can be reconstructed, showing the distribution of the radionuclide in the organ of interest 
(Zanzonico, 2004). A similar but simpler method than PET is single photon emission 
tomography (SPECT). This method has been used to image PK11195 labeled with 
radioactive iodine ([123I]iodo-PK11195) (Versijpt et al., 2000, 2003). 
 
 
Kinetic modeling 
 
For several reasons, radionuclide distributions cannot directly be equated with the density of 
the receptor under study. First, it is likely that the tracer will be metabolized in the body, 
resulting in the generation of one of more radiolabelled metabolites. As a PET scanner only 
measures radioactivity, these compounds are indistinguishable from the original (parent) 
tracer. Second, the measured tracer may or may not be bound to the receptor of interest. 
Third, active pumps may be present that affect the radionuclide distribution. The solution is 
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to develop a tracer kinetic model that translates the radionuclide distributions (in this case 
11C) into receptor density (in this case translocator protein expression). For such a kinetic 
model, measured radionuclide distributions must be measured using a time frame matching 
the kinetics of the tracer. A four-dimensional distribution of the radionuclide (three spatial 
and one time dimension) must be acquired to fit the kinetic model. In general, the kinetic 
model itself is independent of disease condition. Therefore, radionuclide distributions 
measured in a group of (normal) subjects can be used to develop a kinetic model. The ideal 
kinetic model is both sensitive to binding differences and robust to unrelated parameters such 
as noise and blood volume variations. The kinetic model can then be used at an individual 
level to determine receptor density from the measured radionuclide distributions. The 
description above is a simplification of the modeling process. A parameter quantifying 
receptor density is always determined by comparing the concentration as function of time in 
a region of interest (called a time activity curve or TAC) to a reference TAC. This is either a 
TAC in a tissue with negligible receptor binding or in plasma. In the latter case, additional 
concentration measurements in plasma and whole blood are performed, as well as blood 
samples to correct for tracer metabolism. In addition, measured radioactivity concentrations 
have to be corrected for decay, and in general an additional magnetic resonance imaging 
(MRI) scan is used to delineate regions of interest. In the past, kinetic models have been 
determined for many tracers, such as fluorodeoxyglucose for cerebral metabolic rate of 
glucose (Sokoloff et al., 1977), O2 for blood flow (Frackowiak et al., 1980), currently usually 
measured using H2O, flumazenil for central benzodiazepine receptors (Holthoff et al., 1991) 
and raclopride for dopamine D2 receptors (Lammertsma et al., 1996). Alternatively, data 
driven methods exist that do not presume an a priori model, except possibly the assumption 
that binding of the tracer is reversible or irreversible (Cunningham and Jones, 1993, Gunn et 
al., 2002, Logan et al., 1990, Patlak et al., 1983). 
 
 
Outline of this thesis 
 
The aim of this thesis was to develop new and validate existing kinetic models for the analysis 
of (R)-[11C]PK11195 studies with a focus on kinetic models for measuring 
neuroinflammation, more specifically in AD. At the start of writing this thesis, several 
neurological disorders were studied using PK11195, such as AD (Cagnin et al., 2001a , 
Groom et al., 1995), multiple sclerosis (Banati et al., 2000, Debruyne et al., 2003), stroke 
(Pappata et al., 2000), Rasmussen’s encephalitis (Banati et al., 1999), herpes encephalitis 
(Cagnin et al., 2001b), amyotrophic lateral sclerosis (Turner et al., 2004), and multiple system 
atrophy (Gerhard et al., 2003). All of these studies used a reference tissue to quantify uptake, 
either by applying the simplified reference tissue model (Lammertsma and Hume, 1996) or 
by using uptake normalized to a reference region. Use of a reference tissue, however, requires 
validation against a plasma input model. In this way, it is possible to determine whether the 
reference tissue indeed has negligible specific binding. Therefore, in chapter two of this 
thesis, first the optimal tracer kinetic model with plasma input is developed. Chapter three 
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builds on chapter two by using the optimal plasma input model to evaluate various reference 
tissue models. In chapter four, various reference tissues are evaluated for use in AD and the 
stage preceding AD, mild cognitive impairment (MCI, currently also known as prodromal 
AD), and the optimal one is determined. This evaluation includes the cluster analysis method, 
which uses a mathematical approach to determine a reference tissue as opposed to delineating 
a region on a co-aligned MRI scan (Ashburner et al., 1996, Cagnin et al., 2001a, Yaqub et 
al., 2012). In chapter five, inflammation in MCI and AD is evaluated clinically using a variant 
of the previously established reference tissue model. In chapter six, there is a switch from 
neuroinflammation to inflammation outside the brain. A plasma input model for measuring 
inflammation in rheumatoid arthritis in the knee is developed. In chapter seven, the main 
findings of this thesis are summarized, followed by a discussion on future perspectives. 
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Abstract 
 
The compound (R)-[11C]PK11195 (1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-
isoquinoline carboxamide) is a ligand for the peripheral benzodiazepine receptor which, in 
the brain, is mainly expressed on activated microglia. Using both clinical studies and Monte 
Carlo simulations, the aim of this study was to determine which tracer kinetic plasma input 
model best describes (R)-[11C]PK11195 kinetics. Dynamic positron emission tomography 
(PET) scans were performed on 13 subjects while radioactivity in arterial blood was 
monitored online. Discrete blood samples were taken to generate a metabolite corrected 
plasma input function. One-tissue, two-tissue irreversible and two two-tissue reversible 
compartment models, with and without fixing K1/k2 ratio, k4 or blood volume to whole cortex 
values, were fitted to the data. The effects of fixing parameters to incorrect values were 
investigated by varying them over a physiologic range and determining accuracy and 
reproducibility of binding potential and volume of distribution using Monte Carlo 
simulations. Clinical data showed that a two-tissue reversible compartment model was 
optimal for analyzing (R)-[11C]PK11195 PET brain studies. Simulations showed that fixing 
the K1/k2 ratio of this model provided the optimal trade-off between accuracy and 
reproducibility. It was concluded that a two-tissue reversible compartment model with K1/k2 
fixed to whole cortex value is optimal for analyzing (R)-[11C]PK11195 PET brain studies. 
 
 
Introduction 
 
The compound (R)-[11C]PK11195 (1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-
isoquinoline carboxamide) is a specific ligand for the peripheral benzodiazepine receptor. 
This receptor is expressed by mitochondria in cells of the mononuclear phagocyte lineage. 
Expression of this receptor is very low in healthy adult brain, but high in the presence of 
activated microglia, the brain's intrinsic macrophage (Banati et al., 1997). 
 
Both a racemic mixture and the (R)-enantiomer of PK11195, with its higher uptake (Shah et 
al., 1994), have been used as positron emission tomography (PET) tracers for quantifying 
microglia activation. Various neurological disorders such as Alzheimer's disease (Groom et 
al., 1995, Cagnin et al., 2001a), multiple sclerosis (Banati et al., 2000, Debruyne et al., 2003), 
stroke (Pappata et al., 2000), Rasmussen's encephalitis (Banati et al., 1999), Herpes 
encephalitis (Cagnin et al., 2001b), amyotrophic lateral sclerosis (Turner et al., 2004), and 
multiple system atrophy (Gerhard et al., 2003) have been investigated. 
 
Development of a tracer kinetic plasma input model for (R)-[11C]PK11195 brain studies 
 
 
   13 
All these studies used a reference tissue to quantify uptake, either by applying the simplified 
reference tissue model (Lammertsma and Hume, 1996) or by using uptake normalized to a 
reference region (Groom et al., 1995, Versijpt et al., 2003, Debruyne et al., 2003). 
 
Two of these studies used the cerebellum as reference region, one cortical gray matter and 
one the contralateral hemisphere. Five studies used cluster analysis to extract the reference 
tissue because no a priori unaffected region could be defined. The use of a reference tissue 
method, however, has never been validated for (R)-[11C]PK11195 binding. This validation 
requires comparison with a plasma input model. 
 
Unfortunately, to date, no (R)-[11C]PK11195 study using a metabolite corrected plasma input 
function has been reported. The purpose of the present study was, therefore, to determine 
which tracer kinetic plasma input model most accurately describes (R)-[11C]PK11195 
kinetics. 
 
 
Materials and methods 
 
Subjects 
 
Thirteen subjects (two patients with Alzheimer's disease, five patients with mild cognitive 
impairment and six healthy controls) were included in the study. All subjects gave informed 
consent before scanning. The study was approved by the medical ethics committee of the VU 
University Medical Center. In the present study patient data were used only for model 
development. Comparison of results between patients and controls is beyond the scope of the 
present study and will be reported elsewhere. 
 
Scanning protocol 
 
Studies were performed in 3D mode using an ECAT Exact HR+ scanner (CTI/Siemens, 
Knoxville, TN, USA). Characteristics of the scanner have been described elsewhere (Brix et 
al., 1997, Adam et al., 1997). Before tracer administration, a 10-min transmission scan in 2D 
mode was performed, which was used to correct the subsequent emission scan for 
attenuation. Then a [15O]H2O emission scan was acquired, but data from this scan were not 
used in the current study. Finally, a 1 h (R)-[11C]PK11195 emission scan was performed. 
Time frames used were (in order) 1 x 30, 1 x 15, 1 x 5, 1 x 10, 2 x 15, 2 x 30, 3 x 60, 4 x 150, 
5 x 300 and 2 x 600 sec. The first frame was used to correct for background radioactivity 
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from the previous [15O]H2O scan. In all, 224 ± 47 Mbq (R)-[11C]PK11195 with a specific 
activity of 94 ± 34 Gbq/μmol (all data are expressed as mean ± s.d.) at the time of injection 
was administered as a bolus simultaneously with the start of the second frame. Arterial blood 
was withdrawn continuously using an online blood sampling device described previously 
(Boellaard et al., 2001). At 3, 5, 10, 20, 30, 40 and 60 min after tracer injection, blood 
sampling was interrupted briefly for withdrawal of manual samples followed by flushing the 
arterial line with heparinized saline. These manual samples were used to determine plasma 
and whole blood concentrations using a cross-calibrated well counter and plasma metabolite 
concentrations using HPLC as described previously (Greuter et al., 2004). 
 
In addition, T1 weighted magnetic resonance imaging (MRI) scans were acquired using a 1 T 
IMPACT scanner (Siemens Medical Solutions, Erlangen, Germany), which was used for 
segmentation for gray and white matter and for region of interest (ROI) definition. 
 
Image reconstructions 
 
All emission scans were normalized and corrected for attenuation, randoms, dead time, 
scatter and decay. Emission scans were reconstructed using filtered backprojection with a 
Hanning filter with a cutoff of 0.5 times the Nyquist frequency. A zoom factor of 2 and a 
matrix size of 256 x 256 x 63 were used resulting in a voxel size of 1.2 x 1.2 x 2.4 mm and a 
spatial resolution of approximately 7 mm full-width at half-maximum at the center of the 
field of view. Magnetic resonance imaging scans were generated with a voxel size of 0.98 x 
0.98 x 1.49 mm. 
 
Region of interest definition and extraction of time activity curves 
 
The skull was removed from the MRI scans using a brain extraction tool (Smith, 2002), which 
is part of the FMRIB software library (www.fmrib.ox.ac.uk/fsl, Image analysis group, 
Oxford, UK). Deskulled brain and corresponding PET scans were aligned using a mutual 
information algorithm included in the image registration package MIRIT (Maes et al., 1997, 
West et al., 1997). Correct alignment was checked visually. The MRI scan was also used to 
perform a gray/white matter segmentation to generate specific gray and white matter time 
activity curves (TACs). This segmentation was performed using an expectation-
maximization algorithm (Zhang et al., 2001), which is part of the FMRIB software library. 
The segmentation automatically removed the ventricles from the ROIs. Only gray matter 
TACs were used in the present study. 
 
Regions of interest for the cerebellum, temporal lobe, anterior cingulate, hippocampus, 
parahippocampus, amygdala, thalamus, pons and whole cortex were drawn on the fused MRI 
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scan. Regions were drawn for left and right structures separately except for the pons and 
whole cortex. Left and right ROIs were also summed and used as additional ROIs. 
 
Kinetic analysis 
 
Kinetic analyses were performed using dedicated software developed within matlab 5.3 (The 
Mathworks, Natick, MA, USA). A metabolite corrected plasma function was obtained in the 
following way. Plasma/whole-blood ratios obtained from the manual blood samples were 
fitted to an exponential function. The whole blood (online sampler) curve was multiplied 
with this exponential function to obtain the corresponding plasma curve. The 
(R)-[11C]PK11195 parent fraction in the plasma samples was fitted to the function f = 1 - a(2 
- exp(-bt) - exp(-ct)), where f is the parent fraction and a, b and c are the fitted parameters. 
The plasma curve was multiplied with this function to obtain the metabolite corrected plasma 
input function. Various other fits for plasma/whole blood ratio and metabolite level were 
investigated but did not perform any better (Lubberink et al., 2004). Delay between arrival 
of the (R)-[11C]PK11195 bolus in the brain and at the online blood detector was estimated by 
fitting a reversible two-tissue compartment model including blood volume and delay to the 
subjects' whole cortex TAC as described previously (Lammertsma et al., 1996). Separate 
input functions for whole blood (blood volume) and metabolite corrected plasma (tissue 
input) concentrations were used. Delay was then fixed to this value for all other ROIs.  
 
Three different compartment models (Gunn et al., 2001) were fitted to the TACs: a one-tissue 
compartment model, an irreversible two-tissue compartment model and a reversible two-
tissue compartment model and a reversible two-tissue compartment model (figure 1). Again, 
separate input functions for whole blood (blood volume) and metabolite corrected plasma 
(tissue input) concentrations were used in these models. In addition, the reversible two-tissue 
compartment model was investigated using fixed values for K1/k2, k4 and blood volume (Vb). 
K1/k2 is the ration of forward and backward transport rate constants across the blood-brain 
barrier and k4 is the rate of dissociation from the bound compartment. Fixed values of K1/k2, 
k4 and Vb used for all TACs were derived by applying a reversible two-tissue compartment 
model to the whole cortex TAC of each patient. Time activity curves were weighted with the 
square of the frame duration divided by the number of trues in the frame. A weighted version 
of the Akaike information criterion, corrected for small sample sizes (Akaike, 1974, 
Turkheimer et al., 2003), hereafter referred to as the Akaike information criterion (Sugiura, 
1978, Hurvich et al., 1989), was used to determine which model provided the best fit to the 
data. The effect of ROI size on model selection was also examined, as higher noise levels 
(smaller ROIs) are likely to favor models with less parameters. 
 
Fixing parameters or their ratio requires that these parameters are relatively constant over all 
regions for each patient. To validate the assumption that K1/k2 was constant over the brain, 
the variability of K1/k2 for large ROIs (defined as larger than 3 mL, i.e. cerebellum, left, right  
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Figure 1. Compartment models used: (A) one-tissue compartment model, (B) irreversible two-tissue compartment 
model, and (C) reversible two-tissue compartment model. All models were implemented including a parameter for 
blood volume, Vb. Model c was also investigated by fixing K1/k2, k4, or Vb to the whole cortex value. Note that for 
(R)-[11C]PK11195 it is not yet clear whether the nonspecific (ns) signal should be allocated to the free or the specific 
(sp) compartment in models b and c. 
 
and summed frontal lobe, temporal lobe) compared with that of the whole cortex K1/k2 was 
investigated. The relationship between K1/k2 and ROI size was assessed to examine the 
hypothesis that K1/k2 variance measured in small ROIs was mainly because of noise. The 
same procedure was used for k4 and Vb. 
 
Monte Carlo simulations 
 
Monte Carlo simulations were performed to investigate the effects of noise and of fixing 
K1/k2, k4 and Vb to incorrect values on both bias (percentage difference between observed 
and actual values) and reproducibility (expressed as coefficient of variation (COV)) of 
binding potential (BP) and volume of distribution (Vd). Binding potential was defined as k3/k4 
and Vd as K1/k2(1 + BP). In addition, the effects of noise on the Akaike selected model were 
investigated. 
A representative input function and typical parameters found in human data were used to 
create simulated TACs using a reversible two-tissue compartment model (K1 = 0.056 
mL/min/mL, k2 = 0.15 min-1, k4 = 0.040 min-1, Vb = 7.1%). An average BP of 1.5 for the 
whole cortex ROI was derived from clinical data. Usually scanner count rates are used to 
estimate relative variances (and weighting factors for fitting) for all frames of a dynamic 
scan. Because of low extraction fraction of (R)-[11C]PK11195, this would result in very high 
weighting factors for the early frames, when activity is still intravascular and the data contain 
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relatively little information on tissue kinetics. Furthermore, because the effects of the actual 
noise model used on measured BP and Vd values are small (Yaqub et al., 2004), Gaussian 
noise with an s.d. of 7.5 or 15% of the decay corrected activity was used when creating TACs. 
One thousand runs were performed for each noise level. 
 
All models used to fit the patient data were also fitted to the simulated TACs, including the 
models with fixed parameters. Again, the optimal model was selected using the Akaike 
information criterion 
 
In addition, simulations were performed in which the effects of the differences between 
(simulated) correct and fixed K1/k2, k4 and Vb where investigated over a physiologically 
relevant range of parameters. The COVs of the parameters observed among large ROIs 
(cerebellum, left and right frontal lobe, temporal lobe) were used to estimate this range. They 
were calculated using data from all subjects after normalization of values to the individual 
whole cortex value to eliminate variation between subjects and to include only variation 
between ROIs within subjects. Fixed parameters were varied over a range corresponding to 
the correct value plus or minus two s.d. For K1/k2, k4 and Vb , COV of 5%, 32% and 8% were 
used, respectively (Table 1). Simulations were performed using a BP of 1, 2.5 and 4. The 
range of BP from 1 to 2.5 contains 85% of the observed clinical BP values and, in addition, 
the higher BP value of 4 is expected to be near the upper limit of BP in case of (severe) 
microglia activation. One thousand TACs were generated using Gaussian distributed noise 
of 7.5% s.d., which is a reasonably high noise level for ROI data. 
 
 
Results 
 
Clinical evaluation 
 
A representative example of an arterial plasma (R)-[11C]PK11195 TAC is shown in figure 
2A. In addition a corresponding TAC of an ROI (parahippocampus, volume 0.3 mL) is shown 
in figure 2B together with fits to the one-tissue, two-tissue reversible and two-tissue 
irreversible compartment models. The plasma/whole blood ratio was approximately constant 
during the scan and was 1.55 ± 0.08 for the data shown in figure 2. The parent fraction in 
plasma decreased during this scan to 47% after one hour. Metabolism was relatively constant 
across the subjects. 
 
.
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Figure 2. Examples of (A) an arterial plasma (R)-[11C]PK11195 TAC and (B) a tissue region of interest (ROI) 
(parahippocampus) time activity curve (TAC). Panel B shows the measured TAC (circles), together with fits to one-
tissue (solid line), two-tissue irreversible (dashed line), and two-tissue reversible (dotted line) compartment models. 
Activity concentrations were decay corrected. 
 
Figure 3. Results for human data, showing preferred model based on the Akaike information criterion. The 
distribution of preferred model for regions of interest with various volumes is shown. (A) Comparison between one-
tissue (white bar), irreversible (black bar), and reversible two-tissue models (grey bar); (B) preference of two-tissue 
reversible models with fixed K1/k2 (white bar), k4 (black bar), and blood volume (grey bar), as compared with the 
same model with free parameters. 
 
Table 1. Effect of regions of interest (ROIs) size on coefficient of variation (COV) of K1/k2, k4 and blood volume 
(Vb) for the reversible two-tissue compartment model with all parameters free. 
 
    
ROI size (cm3) K1/k2 COV (%) k4 COV (%) Vb COV (%) 
  
  0 - 0.025 34 305 24 
0.025 – 3 18 102 17 
> 3 
4.7 32 7.9 
COVs were calculated after normalization of values to the individual whole cortex value to eliminate variation 
between patients and to include only variation between ROIs within one patient. 
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In case of human data, the reversible two-tissue compartment model was the Akaike selected 
model of choice for 94% of all large ROIs (figure 3A). With decreasing ROI volume, and 
thus increasing noise level, the one-tissue and irreversible two-tissue compartment models 
were selected more frequently compared with the (unfixed) reversible two-tissue 
compartment model. Average parameters for large ROIs derived using the reversible two-
tissue compartment model were K1 = 0.06 ± 0.01 mL min-1 mL-1, k2 = 0.16 ± 0.03 min-1, k3 
= 0.06 ± 0.02 min-1, k4 = 0.04 ± 0.01 min-1, BP = 1.6 ± 0.4, Vb = 7 ± 1% and Vd = 0.9 ± 0.2. 
 
Comparisons between the free and fixed two-tissue compartment models are shown in figure 
3B. Fixed models were not compared with other fixed models and therefore the bars do not 
add up to 100%. In general, models with any of the parameters fixed were selected in 
preference to the model with free parameters. Changing ROI size and thus varying noise level 
affects the selection rate of the models with fixed parameters. With increasing ROI size, 
selection of the model with fixed K1/k2 tends to increase, while that of the model with fixed 
k4 tends to decrease. The model with fixed Vb did not show a trend with varying ROI size. 
The model with fixed K1/k2 was selected most for all ROI sizes. 
 
Variations observed in K1/k2, k4 and Vb over all ROIs and patients decreased with increasing 
ROI size. When ROI size increased from 0 to 0.025 mL to larger than 3 mL, COV decreased 
from 34% to 4.7% for K1/k2, from 305% to 32% for k4 and from 24% to 7.9% for Vb (Table 
1). The latter COVs were calculated using data from all subjects after normalization of values 
to the individual whole cortex value to eliminate variation between subjects and to include 
only variation between ROIs within subjects. 
 
Monte Carlo simulations 
 
Simulations showed that, for models with free parameters, preference for one-tissue and 
irreversible two-tissue compartment models increased with increasing noise level (figure 
4A). In the presence of noise, two-tissue reversible compartment models with fixed 
parameters were selected more often than the model with free parameters (figure 4B), with a 
slight preference for fixed Vb. 
 
To estimate bias and error in BP and Vd for the reversible two-tissue compartment model, 
simulations were performed with typical kinetic parameters and either 7.5% or 15% noise. 
Results obtained with free parameters and with parameters fixed at the simulated (true) values 
are shown in Table 2. Fixing K1/k2 decreased both bias and COV of both BP and Vd. Fixing 
k4 showed the same pattern, except that COV for BP increased slightly. Fixing Vb had little 
effect on COV, but it increased bias. 
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Figure 4. Simulations showing the effects of noise on the Akaike preferred model. (A) Comparison between one-
tissue (white bar), irreversible two-tissue (black bar) and reversible two-tissue models (grey bar); (B) preference of 
two-tissue reversible models with fixed K1/k2 (white bar), k4 (black bar) and blood volume (grey bar) as compared 
with the same model with free parameters. Each bar represents the average of 1000 simulations.  
 
Table 2. Binding potential (BP) and volume of distribution (Vd) bias and coefficient of variation (COV) for the 
reversible two-tissue compartment model with free parameters and with K1/k2, k4, and blood volume (Vb) fixed to 
their true values.  
 
         
Model 7.5% noise 15% noise 
     
 BP Vd BP Vd 
         
 
Bias 
(%) 
COV 
(%) 
Bias 
(%) 
COV 
(%) 
Bias 
(%) 
COV 
(%) 
Bias 
(%) 
COV 
(%) 
         
Unfixed 8.9 25.7 -2.6 15.9 32.6 55.8 -4.7 37.1 
K1/k2 fixed 2.1 17.7 1.2 10.7 5.2 50.2 3.1 30.7 
K4 fixed -1.6 26.6 -0.3 3.9 -4.5 56.6 -1.5 8.1 
Vb fixed 11.8 28.7 -4.7 18 40.1 51.6 -13 34.9 
         
Each value represents the average of 1000 simulations. 
 
To estimate potential bias in BP and Vd as a result of fixing K1/k2, k4 or Vb to incorrect values, 
simulations were performed with these parameters fixed to values over an estimated relevant 
physiologic range (two s.d. of observed values in large ROIs). The noise level used was 7.5%. 
Results from simulations showing bias and COV in measured BP are shown in figure 5, while 
bias and COV in measured Vd are shown in figure 6.  
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Figure 5. Simulations showing the effects of fixing K1/k2 (A, B), k4 (C, D) and Vb (E, F) within the two-tissue 
reversible model on binding potential (BP) bias (A, C, E) and BP coefficient of variation (COV) (B, D, F) at a 7.5% 
noise level. Parameters were fixed at a BP of 1 (open circles), 2.5 (closed circles), and 4 (open triangles) and varied 
over a range corresponding to 2 s.d. variation. Corresponding horizontal lines are bias and COV at the same BP for 
the case where no parameters are fixed. Each value represents an average of 1,000 simulations. 
 
Fixing K1/k2 decreased BP bias (figure 5A) for all BP values simulated and for the major part 
of the range of simulated K1/k2 values. In addition, COV of BP became smaller for most 
simulated BP values (figure 5B). Vd bias (figure 6A) was smaller for almost the entire range 
of fixed K1/k2 values and for all of the simulated BP values. However, COV of Vd was much 
better than for the model with free parameters (figure 6B). This was the case for all simulated 
BP values and for almost the entire range of simulated fixed K1/k2 values. 
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Figure 6. Simulations showing the effects of fixing K1/k2 (A, B), k4 (C, D) and blood volume (Vb) (E, F) within the 
two-tissue reversible model on volume of distribution (Vd) bias (A, C, E) and Vd coefficient of variation (COV) (B, 
D, F) at 7.5% noise level. Parameters were fixed at a Vd of 0.75 (binding potential (BP) is 1, open circles), 1.3 (BP 
is 2.5, closed circles), and 1.9 (BP is 4, open triangles) and varied over a range corresponding to 2 s.d. variation. 
Corresponding horizontal lines are bias and COV at the same BP for the case where no parameters are fixed. Each 
value represents an average of 1,000 simulations. 
 
Fixing k4 decreased BP bias over most of the range of fixed k4 values (figure 5C). However, 
at the lower level of fixed k4 values, bias became larger than that obtained with the reversible 
two-tissue compartment model without fixed parameters. Moreover, COV of BP did not 
improve or even worsened compared with the COV values obtained with the free model 
(figure 5D). When k4 was underestimated by more than 1 s.d. (i.e., 32% or more), bias in Vd 
was much worse than that calculated with the free model (figure 6C). However, COV of Vd 
improved significantly by fixing k4 (figure 6D). 
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For all simulated BP values, fixing Vb resulted in BP bias that was larger than for the free 
model (figure 5E) even for small deviations between true and fixed values. COV of BP was 
comparable between fixed and free models for all simulated values (figure 5F). For Vd, fixing 
Vb resulted in bias similar to that for the free model and COV equal to or larger than that of 
the free model (figure 6E and F). 
 
 
Discussion 
 
Throughout this study, the general approach to finding the best plasma input model for a 
tracer was used. This approach consists in comparing the one-tissue, two-tissue irreversible 
and two-tissue reversible compartment models and selecting the best (Lammertsma, 2003) 
based on independent statistical criteria, in this case the Akaike criterion. Also based on 
additional simulations, the two-tissue reversible model was selected as the optimal 
compartment model for (R)-[11C]PK11195 studies with plasma input. Variations of this 
model with K1/k2, k4 or Vb fixed to whole cortex values were evaluated to see whether a 
decrease of bias and/or COV of the parameters of interest, BP and Vd, could be achieved. 
Again, the Akaike criterion was used to compare these modifications formally. In addition, 
the sensitivity of BP and Vd to fixing K1/k2, k4 or Vb to incorrect values was investigated by 
estimating the resulting bias and COV (of BP and Vd) over the physiologic range of K1/k2, k4 
and Vb. 
 
The reversible two-tissue compartment model was, at low noise levels, the preferred model 
according to the Akaike information criterion (figure 3A). The increased frequency of other 
models for smaller ROI is likely because of higher noise levels as illustrated by the simulation 
studies (figure 4A). Therefore, it is concluded that the reversible two-tissue compartment 
model best describes the underlying physiology. 
 
The model with fixed K1/k2 ratio was, in patient data, the method of choice according to the 
Akaike information criterion (figure 3B). Monte Carlo simulations showed a slight 
preference of the Akaike information criterion for fixing Vb (figure 4B). In these simulations, 
however, parameters were fixed at the exact values and clearly this is not necessarily the case 
for patient data. Simulations with K1/k2 fixed to the correct value indicated that this improved 
both bias and COV of BP and Vd (Table 2). Interestingly, even if K1/k2 was fixed to the wrong 
value, bias was smaller than that for the model with free parameters for most of the K1/k2 
values investigated. As expected, the same was true for COV (figures 5 and 6). Therefore, it 
is concluded that, in general, fixing K1/k2 results in more reliable estimates of both BP and 
Vd. 
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The assumption that K1/k2 is constant may not be correct under certain conditions, for 
example when the blood-brain barrier is disrupted. The results indicate, however, that use of 
fixed K1/k2 values provides acceptable results for a clinically relevant range of K1/k2 
deviations (figures 5 and 6). In case of severe abnormalities, such as in neurotrauma, fixing 
K1/k2 should be further evaluated. 
 
For patient data, fixing k4 also performed better than the free model although to a lesser 
degree than for fixing K1/k2 (figure 3B). Monte Carlo simulations indicated that, when k4 was 
fixed to the correct value, bias decreased for BP and both bias and COV decreased for Vd. 
Especially for high BP values, however, BP bias and COV were very sensitive to 
underestimates of k4 (figure 5). When measuring Vd using the model with fixed k4, COV 
significantly decreased, but bias became unacceptably large when k4 was fixed to the wrong 
value (Figure 6). Given these observations and the difficulty of estimating k4 in practice, as 
indicated by the large COV (32%) for k4 itself, fixing of this parameter cannot be 
recommended. 
 
Similarly, for patient data, fixing Vb was preferred over the free model according to the 
Akaike information criterion, but again to a lesser degree than when fixing K1/k2 (Figure 3B). 
In contrast, in the simulation studies there was a slight preference for fixing Vb (Figure 4B). 
It should be noted, however, that contrary to patient data, parameters were fixed at the exact 
value in these simulations. Despite the preference by the Akaike information criterion, fixing 
Vb (to the correct value) resulted in increased bias in BP and Vd. This apparent discrepancy 
is probably because of the fact that BP and Vd are primarily determined by the tail of the 
TAC, which has less impact on the sum of squares. Therefore, this model is not considered 
useful in practice. 
 
To date, (R)-[11C]PK11195 has only been analyzed using reference tissue models. Cagnin 
and co-workers (Cagnin et al., 2001a) used a clustering method to define a reference tissue. 
Resulting BP values, obtained using a basis function implementation (Gunn et al., 1997) of 
the simplified reference tissue model in combination with the cluster method to obtain a 
reference TAC were much lower (0.07 to 0.46) than in the current study (1.6 ± 0.4) for whole 
cortex ROIs. Similar low BP values were observed in other studies in which a reference tissue 
approach was adopted (Banati et al., 2000). There are several possible explanations for the 
difference between those reference tissue and the present plasma input model BP values. 
 
Firstly, BP obtained from a plasma input model could contain a nonspecific component that 
does not exchange infinitely fast with the free compartment. This would result in an 
overestimation of plasma input model BP. This seems the most likely explanation as it is 
consistent with the finding that nonspecific binding of (R)-[11C]PK11195 in rat is high (Shah 
et al., 1994) and that (R)-[3H]PK11195 binding in the healthy human brain does not bind to 
microglia (Banati et al., 2000). Secondly, if the reference tissue contains a (low) component 
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of specific binding, this would result in underestimation of reference tissue model BP. 
Thirdly, potential differences in nonspecific binding between reference and target tissues 
would result in a bias of reference tissue model BP relative to plasma input model BP. This 
effect would, however, be small if K1/k2 is fixed in the plasma input model. 
 
A further difference between present and previous studies is the use of a gray/white matter 
segmentation in the present study with subsequent use of gray matter TACs. In previous 
studies whole ROI TACs where used. This difference, however, is unlikely to be responsible 
for the observed large difference between reference tissue and plasma input BP, given that 
the average BP, based on the two-tissue reversible model, was 1.6 ± 0.4 for gray and 1.9 ± 
0.5 for white matter. 
 
A labeled metabolite that crosses the blood-brain barrier may also influence results. It has 
been shown, however, that metabolites do not cross the blood-brain barrier in mice (Dumont 
et al., 1999). Therefore, it is expected that the results of the present study are valid for those 
disorders, where the blood-brain barrier remains intact. 
 
The results of the present study indicate that, for human data, a reversible two-tissue 
compartment model best describes (R)-[11C]PK11195 kinetics when using a metabolite 
corrected plasma input function. Clinical data and simulation studies show that the reversible 
two-tissue compartment model with K1/k2 fixed to value for the whole cortex provides the 
optimal trade-off between accuracy and reproducibility for both BP and Vd. 
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Abstract 
 
The tracer (R)-[11C]PK11195 is a marker of activated microglia, which can be used to 
measure inflammation in neurologic disorders. The purpose of the present study was to define 
the optimal reference tissue model based on a comparison with a validated plasma input 
model and using clinical studies and Monte Carlo simulations. Accuracy and reproducibility 
of reference tissue models were evaluated using Monte Carlo simulations. The effects of 
noise and variation in specific binding, nonspecific binding and blood volume were 
evaluated. Dynamic positron emission tomography scans were performed on 13 subjects, and 
radioactivity in arterial blood was monitored online. In addition, blood samples were taken 
to generate a metabolite corrected plasma input function. Both a (validated) two-tissue 
reversible compartment model with K1/k2 fixed to whole cortex and various reference tissue 
models were fitted to the data. Finally, a simplified reference tissue model (SRTM) corrected 
for nonspecific binding using plasma input data (SRTMpl_corr) was investigated. Correlations 
between reference tissue models (including SRTMpl_corr) performed relatively well. Varying 
blood volume had no effect on performance. In the clinical evaluation, SRTMpl_corr and 
SRTM had the highest correlations with the plasma input model (R2 = 0.82 and 0.78, 
respectively). SRTMpl_corr is optimal when an arterial plasma input curve is available. 
Simplified reference tissue model is the best alternative when no plasma input is available.  
 
 
Introduction 
 
The Carbon-11 labeled compound (R)-PK11195 ((R)-1-(2-chlorophenyl)-N-[11C]methyl-N-
(1-methylpropyl)-3-isoquinoline carboxamide) is a ligand for the peripheral benzodiazepine 
receptor. In the brain, this receptor is mainly expressed on activated microglia (Banati et al., 
1997). Both (R)-[11C]PK11195 and [11C]PK11195 have been used as positron emission 
tomography (PET) tracers to study activated microglia in various neurologic disorders. It has 
been used to study stroke (Ramsay et al., 1992, Pappata et al., 2000, Gerhard et al., 2000, 
2005), Alzheimer's disease (Groom et al., 1995, Cagnin et al., 2001a, Versijpt et al., 2003), 
multiple sclerosis (Banati et al., 2000, Debruyne et al., 2002, 2003, Versijpt et al., 2005) and 
various other diseases (Pappata et al., 1991, Banati et al., 1999, 2001, Goerres et al., 2001, 
Cagnin et al., 2001b, 2004, Cicchetti et al., 2002, Gerhard et al., 2003, 2004, 2006, Turner et 
al., 2004, 2005, Venneti et al., 2004, Henkel et al., 2004, Ouchi et al., 2005). Most studies 
have used a reference tissue approach to quantify binding, either by applying the simplified 
reference tissue model (SRTM, Lammertsma and Hume, 1996) or by using uptake 
normalized to a reference region. The use of a reference tissue approach, however, has not 
been validated for (R)-[11C]PK11195. This validation requires comparison with a plasma 
input model. Recently, we have shown that a two-tissue reversible model with fixed K1/k2 is 
optimal for (R)-[11C]PK11195 using a plasma input function (Kropholler et al., 2005). The 
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purpose of the present study was to determine the optimal reference tissue model by 
comparing various reference tissue models with this plasma input model. 
 
 
Materials and methods 
 
Overview of kinetic models 
 
In total, nine models, in which a reference tissue was used, were evaluated. The main 
characteristics of the models are shown in Table 1. A more detailed description of these 
models is given in appendix A. Five of these models were true reference tissue models, in 
that the reference tissue curve was used as the input function. These models were:  
 
A. Simplified Reference Tissue Model (SRTM) (Lammertsma and Hume, 
1996). 
B. Full reference tissue model (FRTM) (Hume et al., 1992). 
C. Reference tissue model with two target and two reference tissue 
compartments (R2T2R). 
D. As R2T2R, but with the same k4 for target and reference tissues, that is k4 = 
k4' (R2T2Rk4). 
E. Reference tissue model with three target and two reference tissue 
compartments and with the same k5 and k6 for both tissues, that is, k5 = k5' 
and k6 = k6' (R3T2Rk5k6). 
 
In two models (specific) binding potential (BPsp) was obtained indirectly through BPsp = (Vd 
- Vd')/Vd', in which the volumes of distribution for target (Vd) and reference (Vd') tissues were 
obtained from plasma input fits: 
 
F. Indirect plasma input model with two target and one reference tissue 
compartment (Vd2T1R). 
G. Indirect plasma input model with two target and two reference tissue 
compartments (Vd2T2R, Lammertsma et al., 1996a). 
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Table 1. Overview of the various reference tissue models. 
 
     
Abbreviation Input 
Number of 
target tissue 
compartments 
Number of 
reference 
tissue 
compartments 
Number of 
fitted 
parameters 
  
   SRTM Reference 1 1 3 
FRTM Reference 2 1 4 
R2T2R 
Reference 2 2 6 
R2T2Rk4 
Reference 2 2 5 
R2T2Rk5k6 
Reference 3 2 6 
VD2T1R Two times 
plasma 
2 1 3 and 5 
VD2T2R Two times 
plasma 
2 2 3 and 5 
SUB2T2R Two times 
plasma 
2 2 3 and 5 
SRTMpl_corr Plasma and 
reference 
1 1 and 2 3 and 5 
 
    
Models can be grouped into direct reference tissue models (SRTM, FRTM, R2T2R, R2T2Rk4 and R
2T2R
k5k6), indirect 
estimates of BP using plasma input estimates of Vd (Vd
2T1R, Vd
2T2R) or total binding potential (SUB2T2R) and methods 
using a combination of plasma and reference inputs (SRTMpl_corr). 
 
In one model BPsp was obtained by subtracting total binding potential of the reference 
(nonspecific) from that of the target (specific + nonspecific) tissue. These total binding 
potentials were obtained from plasma input fits: 
 
H. Plasma input model with two target and two reference tissue compartments 
using subtraction of binding potentials (SUB2T2R). 
 
In the final model BPsp as obtained from SRTM (BPSRTM) was corrected for the contribution 
of nonspecific binding potential (BPns) according to BPsp = BPSRTM ∙ (1 + BPns). Here, BPns 
was obtained from a plasma input fit of the reference tissue: 
 
Evaluation of reference tissue models for the analysis of (R)-[11C]PK11195 studies
 
35 
I. Simplified reference tissue model corrected for non-specific binding using 
a plasma input model with two compartments for the reference tissue 
(SRTMpl_corr). 
 
Two plasma input models were used in this study. One model was used for comparison with 
the reference tissue models. The model was a two-tissue reversible compartment model with 
the K1/k2 ratio fixed to the value obtained for whole cortex. In a previous study, it was 
demonstrated that this is the optimal plasma input model for (R)-[11C]PK11195 (Kropholler 
et al., 2005). The other plasma input model was a three-tissue compartment model with 
different compartments for specific and nonspecific binding (Gunn et al., 2001) and was used 
to generate tissue time-activity curves (TACs) for the Monte Carlo simulations. 
 
Monte Carlo simulations 
 
A typical plasma (R)-[11C] PK11195 TAC was used as input function for the Monte Carlo 
simulations. Tissue TACs were generated using the three-tissue compartment model. Values 
for the various model parameters were based on clinical data: K1 = 0.05 ml min-1 ml-1, k2 = 
0.15 min-1, k4 = 0.2 min-1, BPsp = 0.5, k6 = 0.04 min-1, BPns = 1.5 and blood volume Vb = 7%. 
Uniform Gaussian noise was used with a coefficient of variation (COV) of 7.5%. Simulations 
were performed with parameters fixed at the correct value and with parameters varied over a 
physiologic range. Specific binding potential (BPsp) was varied between 0 and the maximum 
value of 1 observed in the clinical data. Ranges for BPns and Vb were set at ±10% and ±16%, 
respectively, based on previously published subject data (Kropholler et al., 2005). Noise was 
varied between 0% and 10% COV. When BPsp, BPns or Vb was varied, each reported result 
was based on 500 simulations. When parameters were fixed at the correct value, 3000 
simulations were performed. 
 
Accuracy and reproducibility of BPsp were calculated with accuracy expressed as percentage 
bias and reproducibility as the COV. 
 
Subjects 
 
Five subjects with traumatic brain injury (five males, mean age ± s.d. = 39 ± 17 years), 
scanned 28 ± 2 weeks after trauma, and eight elderly healthy subjects (eight males, age 67 ± 
8 years) were included in the study. These two subject groups were selected in order to be 
able to evaluate the various models over the full range of microglia activation seen in clinical 
practice. The study was approved by the medical ethics committee of the VU University 
Medical Center. All subjects gave informed consent before inclusion. In the present study, 
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clinical data were used only for model comparison. Clinical interpretation of the results in 
these subjects is beyond the scope of the present study and will be reported elsewhere. 
 
Scanning protocol 
 
Studies were performed in 3D acquisition mode using an ECAT Exact HR+ scanner 
(CTI/Siemens, Knoxville, TN, USA). Characteristics of this scanner have been described 
elsewhere (Brix et al., 1997, Adam et al., 1997). Before tracer administration, a 10 min 
transmission scan was performed, which was used to correct the subsequent emission scans 
for attenuation. First, a [15O]H2O emission scan was performed, but this scan was not used in 
the present study. Next, a 1-h dynamic (R)-[11C]PK11195 emission scan was performed. 
Time frames used for the (R)-[11C]PK11195 scan were 1 x 30, 1 x 15, 1 x 5, 1 x 10, 2 x 15, 
2 x 30, 3 x 60, 4 x 150, 5 x 300 and 2 x 600 sec. The first frame was used to correct for 
possible background radioactivity resulting from the previous [15O]H2O scan. 328 ± 95 MBq 
(R)-[11C]PK11195 with a specific activity of 83 ± 23 Gbq/μmol at end of synthesis was 
administered as a bolus simultaneously with the start of the second frame. A neuro-insert 
(CTI/Siemens, Knoxville, TN, USA) was used to reduce the contribution of scattered 
photons. Arterial blood was withdrawn continuously using an online blood-sampling device 
described previously (Boellaard et al., 2001). At 3, 5, 10, 20, 30, 40 and 60 min after tracer 
injection blood sampling was interrupted briefly for withdrawal of manual samples, followed 
by flushing of the arterial line with heparinized saline. Plasma and whole-blood activity were 
measured and metabolite levels in plasma were determined using HPLC as described 
previously (Greuter et al., 2004). 
 
In addition, T1 weighted magnetic resonance imaging (MRI) scans were acquired using a 1 T 
IMPACT scanner (Siemens Medical Solutions, Erlangen, Germany). 
 
Image reconstructions 
 
All emission scans were normalized and corrected for attenuation, randoms, dead time, 
scatter and decay. Emission scans were reconstructed using filtered backprojection and a 
Hanning filter with a cutoff of 0.5 times the Nyquist frequency, resulting in a spatial 
resolution of approximately 7 mm full-width at half-maximum at the center of the field of 
view. A zoom factor of two and a matrix size of 256 x 256 x 63 were used resulting in a voxel 
size of 1.2 x 1.2 x 2.5 mm3.  
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Image analysis 
 
The skull was removed from the MRI scans using a brain extraction tool (Smith, 2002), which 
is part of the FMRIB software library (www.fmrib.ox.ac.uk/fsl, Image analysis group, 
Oxford, UK). Deskulled brain and corresponding PET scans were aligned using a mutual 
information algorithm included in the image registration package MIRIT (Maes et al., 1997, 
West et al., 1997). Correct alignment was checked visually. 
 
For trauma patients, a voxel-by-voxel Logan plot (Logan, 2000) was performed to obtain an 
initial overview of regions with high and low binding. Next, these Vd images were used to 
draw regions of interest (ROIs). The thalamus was found to have high Vd and was used as a 
target ROI. In this group, a large cortical region with low Vd was used as a reference tissue 
ROI. For patients suffering from neurotrauma activation of microglia and thus elevated 
(R)-[11C]PK11195 binding might have been present in the cerebellum as well. By defining 
an ROI on initial estimates of (R)-[11C]PK11195 binding it was attempted to obtain a 
reference tissue curve with minimal or no increased (R)-[11C]PK11195 binding. Moreover, 
patient head motion during scanning could not be avoided for this specific patient group and 
by defining a large cortical ROI with low uptake, the effects of patient motion on the quality 
of the reference tissue TAC was further minimized. Note that even with this strategy, it is not 
guaranteed that the reference tissue was free of activated microglia, but binding in these 
reference tissues turned out to be sufficiently low to study relative increases of 
(R)-[11C]PK11195 binding in the thalamus and it did not systematically affect the comparison 
and inter-comparison of reference tissue models against plasma input data. 
 
For the control group of healthy elderly subjects, there is increased microglia activation in 
the thalamus (Cagnin et al., 2001a). This region has been drawn as target ROI. The 
cerebellum was used as a reference tissue region for elderly subjects, assuming low or no 
specific binding in this area, as was also performed by other investigators (Gerhard et al., 
2005), although use of the cerebellum as reference is still a matter of debate. 
 
Kinetic analysis 
 
Kinetic modeling was performed using dedicated software developed within matlab 5.3 (The 
Mathworks, Natick, MA, USA). A metabolite corrected plasma input function was generated 
as described previously (Kropholler et al., 2005). Separate input functions for whole blood 
(to estimate Vb) and metabolite corrected plasma concentrations were used in all (plasma 
input) fits. Delay between injection and arrival of the (R)-[11C]PK11195 bolus was estimated 
by fitting a reversible two-tissue compartment model, including Vb and delay to the subjects' 
whole cortex TAC. Delay was then fixed to this value for all other ROIs. 
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Target ROIs were fitted to the various reference tissue based models. In addition, ROIs were 
fitted to the two-tissue reversible plasma input compartment model with K1/k2 fixed to the 
cortical value. Correlations between this plasma input model and the various reference tissue 
based models were evaluated. 
 
 
Results 
 
Monte Carlo simulations 
 
Biases of the reference tissue models, when all parameters were set to the true values and at 
0% noise level, are shown in Table 2. In addition, bias and COV for 10% noise level are 
given. Several models showed considerable bias, notably SRTM, FRTM and Vd2T2R, and for 
the 10% noise level R2T2R and R3T2Rk5k6. Coefficient of variation was very high for models 
R2T2R, Vd2T2R and SUB2T2R.  
 
Table 2. Bias and coefficient of variation (COV) for the various models at 0 and 10% (COV) noise levels.  
 
         
Model 0% noise 10% noise 
     
 BP bias (%) BP COV (%) BP bias (%) BP COV (%) 
      
   SRTM -61 - -58 30 
FRTM -61 - -57 36 
R2T2R -8 - 
-86 993 
R2T2Rk4 3 - 
18 50 
R2T2Rk5k6 0 - 
99 59 
VD2T1R -23 - 
-22 32 
VD2T2R -76 - 
-72 96 
SUB2T2R -38 - 
-33 97 
SRTMpl_corr 0 - 
8 28 
      
   
Simulations were performed with parameters fixed to the correct value. 3000 runs were performed per value. 
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Figure 1. Bias (A) and coefficient of variation COV (B) of binding potential as a function of noise level, based on 
Monte Carlo simulations. Models shown are SRTM (open squares), FRTM (open diamonds), R2T2R (+ sign), R2T2Rk4 
(open triangles), R3T2Rk5k6 (open circles), Vd2T1R (closed squares), Vd2T2R (closed diamonds), SUB2T2R (x sign) and 
SRTMpl_corr (stars). 
 
All models showed relatively constant BPsp with varying noise levels, except for R2T2R and 
R3T2Rk5k6, which both showed large (~100%) variation in bias (Figure 1A). Coefficient of 
variation increased with increasing noise level, especially for models R2T2R, Vd2T2R and 
SUB2T2R (Figure 1B). Models SRTM, FRTM, R2T2Rk4 and SRTMpl_corr all performed well 
with a maximum COV between 25 and 30%. 
 
All models except SRTM and Vd2T2R showed large variations in bias when BPsp became small 
(Figure 2A). This was especially the case for R3T2Rk5k6, R2T2Rk4 and Vd2T1R with biases larger 
than 100%. Coefficient of variation also became large in the case of small BPsp (Figure 2B). 
Here, Vd2T1R performed best with a COV of 37% at low BPsp, while COV became 
approximately 80% for SRTM and SRTMpl_corr. For all other models, COV became much 
larger than 100%. Coefficient of variation for R3T2Rk5k6 is outside the scale and therefore not 
visible in Figure 2B. 
 
Models R2T2Rk4, SUB2T2R and SRTMpl_corr had little or no bias with varying BPns (Figure 2C). 
All other models showed considerable bias. For all models, COV increased with increasing 
BPns (Figure 2D). The increase was especially large for R2T2R (not visible, COV > 100%), 
R3T2Rk5k6, Vd2T2R and SUB2T2R and smallest for SRTMpl_corr.  
 
Varying Vb did not change bias of the models (Figure 2E). In addition, increasing Vb did not 
result in a change in observed COV, except for R3T2Rk5k6 (Figure 2F). 
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Figure 2. Effects of variation in specific binding (A, B), non-specific binding (C, D) and blood volume (E, F) on 
bias (A, C, E) and coefficient of variation COV (B, D, F) of binding potential, based on Monte Carlo simulations 
using a 7.5% noise level. Models shown are SRTM (open squares), FRTM (open diamonds), R2T2R (open triangles), 
R2T2Rk4 (open circles), R
3T2R
k5k6 (closed squares), Vd
2T1R (closed squares), Vd
2T2R (closed diamonds), SUB2T2R (x sign) 
and SRTMpl_corr (stars). Model R2T2R is not visible in (B), (D) and (E) because all values are outside the scales. 
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Clinical evaluation 
 
Occasionally, some of the reference tissue models provided unrealistic BPsp. These poor fits 
mainly occurred for models with high number of fit parameters. These results were excluded 
from the analysis. For reference models with a low number of fit parameters, such as SRTM 
and SRTMpl_corr, no poor fits were observed. Correlation coefficients of the regressions 
between the two-tissue reversible plasma input model with K1/k2 fixed to whole cortex and 
the reference tissue models are shown in table 3. Scatter plots between plasma input and 
reference tissue BP for the best reference tissue models are shown in Figure 3. Note that the 
errors in SRTMpl_corr were calculated assuming no correlation between BPsp and BPns, which 
is strictly not valid. The SRTMpl_corr model performs best, followed by SRTM and FRTM. 
The indirect methods (Vd2T1R and Vd2T2R) and especially the direct reference tissue models 
R3T2Rk5k6 and R2T2R did not perform very well. 
 
Table 3. Correlation coefficients between binding potential as obtained from the various reference tissue models 
and that from the two-tissue reversible plasma input model with K1/k2 fixed to the whole cortex. 
 
  
Model name R2 
  
SRTM 0.78 
FRTM 0.74 
R2T2R 
0.00 
R2T2Rk4 
0.49 
R2T2Rk5k6 
0.04 
VD2T1R 
0.32 
VD2T2R 
0.32 
SUB2T2R 
0.45 
SRTMpl_corr 
0.82 
 
 
 
Discussion 
 
Monte Carlo simulations 
 
When evaluating the results from the simulations, SRTM performed equally well or better 
than FRTM in all aspects. 
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Figure 3. Correlations between binding potential calculated using various reference tissue models and the two-tissue 
reversible plasma input model with K1/k2 fixed to the whole cortex value. Results are shown from neurotrauma 
subjects (open squares) and from elderly normal controls (open triangles). Only results for models with a correlation 
coefficient of more than 0.7 are shown. 
 
When the correct parameter values were used in the simulations, all models show bias at the 
10% noise level (Table 2). For SRTM and FRTM, a bias of approximately 1/(1 + BPns) is 
expected because of the non-specific binding. Bias, however, is acceptable if it remains 
relatively constant under physiologic variation between region and subjects. In contrast, large 
COV, as observed in R2T2R, Vd2T2R and SUB2T2R (~100% or more), seriously limits 
applicability. 
 
As noise levels vary and, to a large degree, are unknown, bias for a good reference tissue 
model should be insensitive to changes in noise level. Models R2T2R and R3T2Rk5k6 showed 
biases that were very dependent on noise level (Figure 1A), limiting their applicability in 
clinical studies. 
 
Measuring small BPsp with high accuracy and reproducibility proved to be difficult (Figure 
2A and 2B). This is expected as it is difficult to distinguish a small specific signal from the 
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much larger non-specific signal. Both SRTM and SRTMpl_corr performed relatively well here, 
although increase in bias for SRTMpl_corr was substantial. The results for small BPsp seriously 
limit the applicability of models Vd2T2R and SUB2T2R (high COV), Vd2T1R (high bias) and 
R2T2R, R2T2Rk4 and R3T2Rk5k6 (high bias and COV). 
For several models (SRTM, R2T2R, R2T2Rk4, Vd2T1R and Vd2T2R, the change in bias because of 
variations in BPns was smaller (Figure 2C) than the change caused by variation in BPsp, and 
therefore less important in model evaluation. Increased COV with increasing BPns (Figure 
2D) for R3T2Rk5k6, Vd2T2R and SUB2T2R is a serious limitation of these models. 
 
Varying Vb had little effect on bias and COV. For R3T2Rk5k6, increasing Vb resulted in a 
substantial, but acceptable increase in COV. 
 
Clinical evaluation 
 
In general, correlations between reference tissue model BPs and plasma input BPs were low 
due to both high noise levels in (R)-[11C]PK11195 studies (low uptake and high nonspecific 
binding) and different effects of nonspecific binding on plasma input and reference tissue 
models. 
 
Only correlations from SRTMpl_corr, SRTM and FRTM were acceptable. The poor 
performance of R2T2R, R3T2Rk5k6 and to a lesser degree R2T2Rk4 is probably due to the increased 
number of fitting parameters. The model SUB2T2R suffers from an increase in COV because 
BPsp is calculated by subtracting two fitted parameters (of similar magnitude) with resulting 
error propagation. Similarly, models Vd2T2R and Vd2T1R also calculated BPsp by combining 
two Vd values of similar magnitude resulting in unfavorable error propagation, explaining 
the poor correlations for these models (Table 2). 
 
The results indicate that SRTM BPsp correlate well with plasma input BPs. From a theoretical 
point of view, a perfect correlation is not expected because the plasma input model measures 
the sum of BPsp and BPns while SRTM measures specific BP alone. Since nonspecific binding 
is high (for subjects with neurotraumatic injury, plasma input BPs are in the order of ~2 while 
SRTM BPs are ~0.5), the plasma input model cannot be treated as the golden standard. The 
influence of BPns on the calculated BPsp using reference tissue models will further decrease 
the reproducibility of measured BPsp (due to the bias of 1/(1+ BPns) in BPsp) and to a lesser 
extend for SRTMpl_corr. Therefore, SRTMpl_corr is an improvement over SRTM. However, by 
including a correction for nonspecific binding, systematic and statistical errors in metabolite 
corrections might result in errors and increased uncertainties in observed specific binding 
using SRTMpl_corr. 
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Limitations 
 
The reference tissues used in this study were cerebellum for the elderly healthy subjects and 
an (apparently) unaffected cortical region for neurotrauma patients. The cerebellum has been 
used previously (Groom et al., 1995, Banati et al., 1999, Versijpt et al., 2003, Gerhard et al., 
2005), while an unaffected region was chosen to approximate those areas that would be found 
by cluster analysis as used in several reports (Banati et al., 2000, 2001, Cagnin et al., 2001a, 
2001b, Gerhard et al. 2003, Turner et al. 2004). Both these reference regions might, however, 
not be 'perfect' as reference tissue, because increased specific binding in these structures 
cannot be excluded. Increased specific binding in the reference tissue would result in an 
underestimation of specific binding in the target areas. As in all models, the same reference 
region was used, possible presence of (a small degree of) specific binding in the reference 
region will only have a small effect on the comparisons based on the clinical data. For clinical 
data, the observed correlations between plasma input and reference tissue models could be 
reduced because of specific binding in the reference tissue, but it should affect all reference 
tissue models to a similar extent. Therefore, it should still be possible to identify the optimal 
reference tissue model. 
 
The present study was not concerned with identifying the 'best' reference tissue. Further 
studies are required to identify optimal reference tissues for different clinical conditions 
(stroke, Alzheimer's disease, neurotrauma, etc.). In addition, further studies are needed to 
assess methods that enable automatic extraction of reference tissue curves (e.g. cluster 
analysis). 
 
General conclusion 
 
In this study, several reference tissue models were evaluated using both Monte Carlo 
simulations and clinical data. Among these models, SRTMpl_corr and SRTM performed best 
both in Monte Carlo simulations and in clinical evaluation. The simplified reference tissue 
model does not require a metabolite corrected plasma input curve, and is therefore 
recommended for studies when only a reference tissue input is available. SRTMpl_corr, in 
which a correction for bias due to nonspecific binding is performed, performs better than 
SRTM, especially when measuring low BPsp. It has the advantage over the two-tissue 
reversible compartment model with K1/k2 fixed to whole cortex that it measures BPsp instead 
of the sum of BPsp and BPns which is very relevant for (R)-[11C]PK11195 as it is a tracer with 
large BPns. Therefore, SRTMpl_corr is recommended for analyzing (R)-[11C]PK11195 studies 
when a metabolite corrected plasma input curve is available, while SRTM is recommended 
when only a reference tissue input can be used. 
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Appendix A 
 
Overview of new reference tissue models 
 
In the present study, eight reference tissue models and one model with both plasma and 
reference input were evaluated. Not all of these models are in common use. Therefore, in this 
appendix, the most general of these reference tissue models, that is, the model with three 
target tissue and two reference tissue compartments (R3T2R, Figure A1) will be described in 
more detail and its operational equation will be derived. The operational equations for the 
other models can easily be derived from that of R3T2R by setting appropriate parameters to 
zero. 
 
The general solution for a reversible plasma input compartment model, when neglecting 
blood volume, is 
 
 
where Ct is the target ROI concentration, Cp the metabolite corrected plasma input 
concentration and H(t) the impulse response function of the system. For an n-compartment 
reversible plasma input model, H(t) has the form (Gunn et al., 2001): 
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Figure A1. Schematic diagrams of the reference tissue compartment model with three target tissue compartments 
and two reference tissue compartments. 
 
The transfer function of the system is its Laplace transform H˜(s) and is given by 
 
 
The corresponding equations for a reference tissue model with m reversible target and n 
reversible reference tissue compartments are 
 
 
 
 
 
In these equations, R1=K1/K'1 and Cr(t) the concentration in the reference tissue. The various 
Φi and Θi are functions of the kinetic parameters. If the plasma input transfer functions for 
the target and reference regions are H˜TP(s) and H˜RP(s), respectively, then the plasma input 
transfer function for the reference tissue model H˜TR(s) is (Gunn et al., 2001) 
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As the target tissue contains three compartments and the reference tissue two, the final 
reference tissue model has five compartments. Substituting the transfer functions for the two 
tissues into the equation above results in 
 
 
Next, ΦTRi and ΘTRi, where i is either 1, 2, 3 or 4, will be expressed as a function of ΦTPj, ΘTPj, 
ΦTRk and ΘTRk of the original plasma input models. Both the left- and right-hand sides of the 
equation above must have poles at s = -ΘTRi, where i is either 1, 2, 3 or 4. If all poles are 
unique, then it can be assumed without loss of generality that 
 
 
Both expressions for H˜TR(s) must be equal in neighborhoods of s = -ΘTRi, where i is either 1, 
2, 3 or 4, and thus it can be directly seen that 
 
 
Taking the limit of s → -ΘTR4 results in  
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In the vicinity of s → -ΘTR4, where H˜TR(s) → ∞, the lower order terms on the left-hand side 
can be ignored. Rearranging terms on the right-hand side results in 
 
 
 
which can be rearranged into 
 
 
 
 
and thus 
 
and 
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The expressions of ΦTPi, ΘTPi, ΦRPi and ΘRPi are (Gunn et al., 2001): 
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and 
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Models R2T2R, R2T2Rk4 and R3T2Rk5k6, derived from R3T2R, assume a constant K1/k2 ratio 
between target and reference tissues (i.e. k2' = k2∙K1'/K1 = k2/R1). Model R3T2Rk5k6 can be 
derived by substituting k2' by k2/R1, k5' by k5 and k6' by k6. The fitted parameters for this 
model are R1, k2, BPsp, k4, BPns and k6. Model R2T2R can be derived by reducing the target 
tissue with one compartment and again by assuming a constant K1/k2 ratio for target and 
reference tissues. The fitted parameters for this model are R1, k2, BPsp, k4, BPns and k6'. BPns 
equals k5'/k6' and BPsp equals k3/k4 - k5/k6. The equations for R2T2R can be derived by 
substituting k2' by k2/R1, by setting k5 to zero and by neglecting k6. Model R2T2Rk4 can be 
derived from R2T2R by renaming k5' to k3', k6' to k4' and by fitting k4' and k4 by a common 
parameter. The fitted parameters for this model are R1, k2, BPsp, BPns and k4. The equations 
for this model can be derived by replacing k6' by k4 in the model R2T2R. 
 
Model Vd2T2R uses a two-tissue reversible compartment model for both target and reference 
regions. Like all other plasma input models used in the present study, it includes a blood 
compartment and uses different time activity curves for blood and (metabolite corrected) 
plasma concentrations. The standard two-tissue reversible compartment model was used for 
the reference region. A modified two-tissue reversible compartment model with the K1/k2 
ratio fixed to the ratio of the reference tissue was used for the target region as described 
previously (Kropholler et al., 2005). The BPsp is then estimated indirectly using BPsp = Vd/( 
Vd - Vd'), in which Vd is K1/k2∙(1+k3/k4) and Vd' is defined correspondingly. The fitted 
parameters for this model are K1, k2, k4, BP and Vb for the target region and K1', k6', BP and 
Vb' for the reference region. Model Vd2T1R uses a one-tissue compartment model for the 
reference region, a two-tissue reversible compartment model for the target region and the 
same formula BPsp = Vd/( Vd - Vd'). For the one-tissue reference region, Vd' = K1'/k2'. The 
fitted parameters for this model are K1, k2, k4, BP and Vb for the target region and K1', k2' and 
Vb' for the reference region. The model SUB2T2R uses the same plasma input models as Vd2T2R 
but calculates BPsp by subtracting the estimated BP of the reference region from the BP of 
the target region. 
 
The simplified reference tissue model corrected for non-specific binding, SRTMpl_corr, 
estimates BPns using the two-tissue reversible compartment model with plasma input and 
BPsp using SRTM (Lammertsma et al., 1996b). The specific binding potential is then 
corrected for non-specific binding using the equation BPsp = BPspSRTM ∙(1 + BPns) where 
BPspSRTM is BPsp calculated using SRTM. 
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Abstract 
 
Inflammation in Alzheimer's disease (AD) may be assessed using (R)-[11C]PK11195 and 
positron emission tomography. Data can be analyzed using the simplified reference tissue 
model, provided a suitable reference region is available. This study evaluates various 
reference regions  for analyzing (R)-[11C]PK11195 scans in patients with mild cognitive 
impairment (MCI) and probable AD. Healthy subjects (n = 10, 30 ± 10 years and n = 10, 70 
± 6 years) and patients with MCI (n = 10, 74 ± 6 years) and probable AD (n = 9, 71 ± 6 years) 
were included. Subjects underwent a dynamic three-dimensional (R)-[11C]PK11195 scan 
including arterial sampling. Gray matter, white matter, total cerebellum, cerebrum and cluster 
analysis were evaluated as reference regions. Both plasma input binding potentials of these 
reference regions (BPPLASMA) and corresponding reference region input binding potentials of 
a target region (BPSRTM) were evaluated. Simulations were performed to assess cluster 
analysis performance at 5% to 15% coefficient of variation noise levels. Reasonable 
correlations for BPPLASMA (R2 = 0.52 to 0.94) and BPSRTM (R2 = 0.59 to 0.76) were observed 
between results using anatomic regions and cluster analysis. For cerebellum white matter, 
cerebrum white matter and total cerebrum a considerable number of unrealistic BPSRTM 
values were observed. Cluster analysis did not extract a valid reference region in 10% of the 
scans. Simulations showed that potentially cluster analysis suffers from negative bias in 
BPPLASMA. Most anatomic regions outperformed cluster analysis in terms of absence of both 
scan rejection and bias. Total cerebellum is the optimal reference region in this patient 
category. 
 
 
Introduction 
 
Alzheimer's disease (AD) is a neurodegenerative disease associated with activation of 
normally dormant microglia cells (Cagnin et al., 2001a). These microglia cells are the brain's 
intrinsic macrophages (Kreutzberg, 1996). Activated microglia express the peripheral 
benzodiazepine receptor, but expression of this receptor on other constituents of the brain is 
low (Banati et al., 2000). Thus compounds that bind to the peripheral benzodiazepine receptor 
can be used to image activated microglia. 
 
PK11195 is a specific ligand for the peripheral benzodiazepine receptor, which has been used 
to investigate microglia activation using either positron emission tomography (PET) or single 
photon emission computed tomography. Unfortunately, analysis of (R)-[11C]PK11195 PET 
scans has proven to be difficult because of its low specific to nonspecific binding ratio and 
its very low extraction fraction (Kropholler et al., 2005). Consequently, attention should be 
paid towards optimizing methods for extracting the specific signal. Currently, more 
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promising peripheral benzodiazepine receptor tracers are under investigation, such as 
DAA1106 (Maeda et al., 2004, Ikoma et al., 2007) and vinpocetine (Gulyas et al., 2002a, 
2002b, 2002c, 2005). 
 
Several (R)-[11C]PK11195 studies investigating AD have been undertaken. Two studies used 
PET (Groom et al., 1995, Cagnin et al., 2001a) and one single-photon emission tomography 
(Versijpt et al., 2003). Only Cagnin and co-workers (Cagnin et al., 2001a) used the pure (R)-
enantiomer, which has higher binding than the (S)-enantiomer (Shah et al., 1994), whereas 
the other studies used a racemic mixture. To determine the degree of binding in the regions 
of interest (ROI), all three studies used a tracer kinetic model depending on a reference region 
either by using the simplified reference tissue model (SRTM, Lammertsma and Hume, 1996) 
or by normalizing activities. Two groups (Groom et al., 1995, Versijpt et al., 2003) used 
cerebellum as reference region, whereas a different group used a cluster analysis method to 
derive the reference region (Ashburner et al., 1996, Cagnin et al., 2001a). This cluster 
analysis approach is commonly used to analyze (R)-[11C]PK11195 scans (Banati et al., 2000, 
2001, Cagnin et al., 2001b, 2004, Gerhard et al., 2003; Turner et al., 2004, 2005, Henkel et 
al., 2004). Recently, a comparison of parametric methods for analysis of (R)-[11C]PK11195 
was published by our group (Schuitemaker et al., 2007). 
 
For analysis of (R)-[11C]PK11195 PET scans in AD and mild cognitive impairment (MCI), 
it has been argued that the cerebellum may be inadequate as a reference region, as activated 
microglia could be present (Braak and Braak, 1991). Therefore, cluster analysis, which 
defines groups of voxels with 'normal' (R)-[11C]PK11195 binding, could be an alternative 
method, as this method does not depend on predefined regions. However, this method has 
not been fully validated yet. It is of interest to note that the two PET studies of Groom (Groom 
et al., 1995) and Cagnin (Cagnin et al., 2001a) produced conflicting results. It is likely that 
these different results are, at least in part, because of differences in methodology. Clearly, 
there is a need to evaluate which method is optimal for defining a reference region for 
(R)-[11C]PK11195 studies in AD. This is especially important for multicenter studies on MCI. 
 
The purpose of this study was to compare various reference region definitions and to evaluate 
their applicability for analyzing differences in microglia activation in MCI and AD subjects. 
Moreover, simulations were performed to evaluate the performance of the cluster analysis 
approach under the influence of varying blood fractions (Vb) and number of extracted 
clusters. 
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Materials and methods 
 
Subjects 
 
Four groups were included, namely younger healthy subjects (n = 10, 7 male subjects, age 
30 ± 10 years), elderly healthy subjects (n = 10, 6 male subjects, age 70 ± 6 years), patients 
diagnosed with amnestic MCI (n = 10, 6 male subjects, age 74 ± 6 years) according to 
Petersen criteria (Petersen et al., 1999) and subjects diagnosed with probable AD (n = 9, 6 
male subjects, age 71 ± 6 years), meeting NINCDS-ADRDA criteria (McKhann et al., 1984). 
Average (± s.d.) mini mental state examination scores (Folstein et al., 1975) were 29 ± 1 for 
elderly healthy subjects, 26 ± 1 for MCI patients and 22 ± 3 for AD patients, respectively. 
Control subjects had a normal physical and neurologic examination, including screening 
laboratory assessments and had a normal magnetic resonance imaging (MRI) scan, which 
was evaluated by a neuroradiologist. The study was approved by the medical ethics 
committee of the VU University Medical Center and all experiments were performed in line 
with the recommendations of the Helsinki declaration. All subjects gave written informed 
consent before inclusion. Data were only used for comparison of methods. Clinical results 
are beyond the scope of the present study and will be reported elsewhere. 
 
Scanning protocol 
 
All subjects underwent a 1-h dynamic brain scan in three-dimensional mode performed on a 
Siemens/CTI ECAT EXACT HR+ scanner (CTI/Siemens, Knoxville, TN, USA). 
Characteristics of this scanner have been reported elsewhere (Brix et al., 1997, Adam et al., 
1997). Frame durations of the scan were, in order, 1 x 15, 1 x 5, 1 x 10, 2 x 15, 2 x 30, 3 x 
60, 4 x 150, 5 x 300 and 2 x 600 sec. A bolus of 400 ± 60 MBq/μmol of (R)-[11C]PK11195 
with a specific activity of 65 ± 32 Gbq/μmol at time of injection was injected at the start of 
the scan. A neuroinsert (CTI, Knoxville, USA) was used to decrease scatter from outside the 
field of view. Before tracer injection, a two-dimensional transmission scan was performed, 
which was used to correct the subsequent emission scan for attenuation. Arterial blood was 
withdrawn continuously using a blood-sampling device described previously (Boellaard et 
al., 2001). At set times (3, 5, 10, 20, 30, 40 and 60 min after injection), continuous blood 
sampling was interrupted briefly for withdrawal of manual samples followed by flushing of 
the arterial line with heparinized saline. Radioactivity concentrations of (R)-[11C]PK11195 
in plasma and whole blood of the manual samples were measured using a cross-calibrated 
well counter and metabolites in plasma using high pressure liquid chromatography analysis, 
as described previously (Greuter et al., 2005). 
In addition, all subjects underwent a T1 weighted MRI scan on a 1T IMPACT scanner 
(Siemens Medical Solutions, Erlangen, Germany). This scan was used for gray/white matter 
segmentation and for ROI definition. 
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Image reconstruction 
 
All emission scans were normalized and corrected for attenuation, randoms, dead time, 
scatter (Watson, 2004) and decay. Emission scans were reconstructed using a filtered back 
projection with a Hanning filter with cutoff at 0.5 times the Nyquist frequency. A zoom factor 
of 2 and a matrix size of 256 x 256 x 63 were used, resulting in a voxel size of 1.2 x 1.2 x 2.4 
mm and a reconstructed spatial resolution of approximately 7 mm full-width at half-
maximum at the center of the field of view. 
 
Region of interest definition and extraction of time-activity curves 
 
The skull was removed from the MRI scans using a brain extraction tool (Smith, 2002), which 
is part of the FMRIB software library (www.fmrib.ox.ac.uk/fsl, Image analysis group, 
Oxford, UK). Deskulled brain and corresponding PET scans were aligned using a mutual 
information algorithm included in the image registration package MIRIT (Maes et al., 1997, 
West et al., 1997). Correct alignment was checked visually. Both total cerebellum and 
cerebrum ROI were drawn manually on the coregistered MRI scans. 
 
The MRI was segmented into gray and white matter (Zhang et al., 2001) and separate gray 
and white matter cerebellum and cerebrum ROI were defined. The software used for this 
segmentation was also part of the FMRIB software library. To evaluate performance of the 
various reference regions, parametric binding potential (BP) images (Ichise et al., 1996) were 
used to draw a data-driven (target) ROI around the thalamus. In agreement with a previous 
observation in elderly healthy subjects and AD patients (Cagnin et al., 2001a), highest 
binding was observed in this region. In addition, by including young healthy subjects, the 
thalamus ROI provided the largest range of possible BP values for the present comparison of 
reference regions. The cluster region was extracted as described elsewhere (Banati et al., 
2000). This region represents a group of voxels with similar kinetics and does not correspond 
to an actual 'anatomic' reference region, such as cerebellum or pons. Nevertheless, as the 
corresponding time-activity curve (TAC) and those of cerebellum and cerebrum were 
compared as input curves in SRTM, the term reference region will also be used for the cluster 
region. Software to perform this clustering, written in Matlab (The Mathworks, Natick, MA, 
USA), was kindly provided by the MRC Clinical Sciences Centre (Faculty of Medicine, 
Imperial College, London, UK). To produce results comparable with previous studies, where 
no plasma input was used, the cluster with visually the lowest BP was selected as reference 
region. Because at several occasions clustered regions did not correspond to anatomic 
structures, they were evaluated visually to ensure that tissue was selected. Ten clusters were 
extracted from each scan (Banati et al., 2000). 
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Kinetic analysis 
 
Kinetic modeling was performed using dedicated software developed within Matlab. A 
metabolite-corrected plasma input function was obtained as follows. Plasma/whole blood 
concentration ratios obtained from the manual blood samples were fitted to an exponential 
function. The whole-blood (online sampler) curve was multiplied with this exponential 
function to obtain the corresponding (total) plasma curve. The (R)-[11C]PK11195 parent 
fraction in the plasma samples was fitted to the function f = 1 - a((2 - exp(-bt) - exp(-ct)) 
where f is parent fraction and a, b and c are positive fitted parameters. The plasma curve was 
multiplied with this function to obtain the metabolite-corrected plasma input function. Delay 
between arrival of the (R)-[11C]PK11195 bolus in the brain and at the online blood sampler 
was estimated by fitting a reversible two-tissue compartment model including blood volume 
and delay to the subjects' whole cortex TAC. Delay was then fixed to this value for all other 
ROI of the subject. 
 
Reference region BP (i.e., nonspecific binding) was obtained using a reversible two-tissue 
compartment model (Kropholler et al., 2005), containing a blood volume term with separate 
inputs for metabolite-corrected plasma (input to tissue) and whole blood (fractional blood 
volume) and is denoted by BPPLASMA. To allow equal comparison between reference regions 
the K1/k2 ratio was not fixed. Binding potential in a target region was derived using SRTM 
(Lammertsma and Hume, 1996) and is denoted as BPSRTM. This BPSRTM was also corrected 
for nonspecific binding by multiplying it with 1 + BPPLASMA (Kropholler et al., 2006), which 
is then denoted as BPSRTM_CORR. 
 
Simulations 
 
Simulations were performed to evaluate the ability of the cluster analysis algorithm to 
separate voxels with high and low BP. Because (R)-[11C]PK11195 uptake in brain is very 
low (K1 ~ 0.05 ml/min/ml) and the concentration in blood decreases rather slowly (50% 
parent fraction after 1 h), the shape of the (R)-[11C]PK11195 TAC are, to a large extend, 
determined by the radioactivity concentration in the blood. Therefore, the sensitivity of 
cluster analysis BPPLASMA to physiologic variation in Vb was also determined. Volumes with 
simulated TAC and either 5%, 10% or 15% coefficient of variation (COV) noise level were 
generated and grouped into clusters. Normal tissue was simulated using a two-tissue 
reversible compartment model and kinetic parameters reported previously (Kropholler et al., 
2005), namely K1 = 0.05 ml/min/ml, k2 = 0.15 min-1, k4 = 0.04 min-1, BP = 1.5 and Vb = 0.06. 
In the subject population, a variation in BP of 0.7 and in Vb of 0.03 was found. Volumes 
containing both an ROI with increased BP (BP = 2.2) and an ROI with increased Vb (Vb = 
0.09) were simulated. Simulated volume size was 32 x 32 x 15 voxels. Regions of interest 
with different kinetics were 9 x 9 x 9 voxels large. In clinical studies, 10 clusters were used 
to represent structures such as tissue, blood vessels, skull and ventricles. In the simulations 
only three regions with different characteristics were present. To account for this smaller 
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number two, three or four clusters were extracted representing a lower, the same of a higher 
number of clusters than present in the data. The extracted cluster ROI with lowest BPPLASMA 
was used as reference region cluster. BPSRTM using the cluster analysis ROI as reference 
region and BPPLASMA of the cluster analysis ROI were evaluated. A noiseless TAC with the 
same kinetic parameters as the high BP ROI was used as target ROI and the effects of noise 
level and number of clusters on BPSRTM values were evaluated. 
 
 
Results 
 
Clinical evaluation 
 
The clustering algorithm resulted in a rough separation between gray and white matter, blood 
vessels and cerebrospinal fluid (Figure 1A and B). In total, 10 clusters were extracted and the 
TAC with the lowest BPPLASMA was used as reference region TAC. For four out of 39 subjects 
clustering did not result in physiologically meaningful clusters (Figure 1C). Results from 
these subjects were not included in the comparative analyses. No correlation was observed 
between unidentifiable clusters and injected dose. The distribution of voxels over the 10 
clusters decreased from 27 ± 4% of voxels in the largest cluster to 20 ± 4% in the second 
largest and 1 ± 0.3% in the smallest cluster. The cluster containing the largest number of 
voxels (partially) represented skull in more than 80% of the cases. For several subjects fitting 
a plasma input model to the cluster TAC provided poor results (very high BP or high COV 
associated with fitted BP). The BPPLASMA values were excluded from analysis when COV 
was larger than 60% or when BPPLASMA itself was > 5. One subject was rejected because of 
inconsistent BPPLASMA results between ROI, which was not observed for the other subjects. 
Rejection of fits was assessed independently for different kinetic models, that is subjects that 
gave unrealistic results for one model were included when analyzing other models. The 
number of excluded scans is reported in Table 1. It can be seen that a substantial number of 
fits were rejected, with the highest number for BPSRTM (and consequently also BPSRTM_CORR) 
using cerebrum white matter as reference region input. This high rejection rate indicates that 
this white matter region is not a suitable reference tissue input for the gray matter thalamus 
region. For most reference regions, the rejection rate of BPSRTM fits was < 10%. The rejection 
rate of BPSRTM_CORR was higher, as this analysis also requires an acceptable plasma input fit 
of the reference region itself. Often the same fit is rejected for several reference regions. 
Rejection of a fit for several reference regions results in only one scan excluded in the total 
comparison, because it is the same subject for which several TACs result in rejected fits. 
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Figure 1. Cluster images of (A) one elderly, (B) one AD and (C) one young subject. Each color corresponds to a 
cluster index and contains voxels having similar TAC shapes, for example red corresponds with large blood vessels, 
light blue with gray matter, dark blue with skull and green with white matter. A and B show that clustering results 
in a rough separation into gray and white matter. Occasionally clustering did not provide meaningful clusters. 
 
Reasonable correlations were observed between total binding of anatomic and cluster ROI 
obtained using a plasma input model (BPPLASMA). Scatter plots between total cerebellum and 
cluster analysis BPPLASMA and between cerebrum gray matter and cluster analysis are shown 
in figures 2A and B. Correlations were highest between BPPLASMA from cerebrum and cluster 
analysis (R2 = 0.93, 0.92 and 0.94 for gray matter, white matter and total cerebrum, 
respectively) and considerably lower between cerebellum and cluster analysis (R2 = 0.52, 
0.68 and 0.69, respectively). Measured BPPLASMA values for the different subject groups are 
shown in figure 3A. No statistical significant differences were observed between groups. 
 
The BPSRTM values were rejected if COV of the fitted BP was larger than 70% or when BP 
itself was either larger than 1 or smaller than 0. A high number of unrealistic BPSRTM results 
were observed when cerebellum white matter, total cerebrum or cerebrum white matter was 
used as reference region (6, 6 and 13, respectively; table 1). This suggests that these ROI are 
not suitable as reference regions. To increase statistical power, these ROI were excluded from 
BPSRTM analysis. Correlations were observed between target BPSRTM calculated using the 
various ROI as reference region. Correlation was calculated between target BPSRTM values 
using total cerebellum and cluster analysis as reference region (figure 2C, R2 = 0.76). Lower 
correlations were observed between the use of cluster analysis reference region and cerebrum 
gray matter (figure 2D, R2 = 0.71) and between the use of cluster analysis reference region 
and cerebellum gray matter ( R2 = 0.59). Measured BPSRTM values for the different groups 
are shown in figure 3B. No statistically significant differences were observed between 
groups. Little variation was observed in the COV between ROI or between subject groups. 
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High correlations were observed between BPSRTM_CORR values (i. e. BPSRTM corrected for non-
specific binding) of the target region measured using the various reference region methods. 
Correlation coefficients between the use of cluster analysis as reference region and the use 
of either cerebellum gray matter, total cerebellum or cerebrum gray matter were R2 = 0.86, 
0.86 and 0.83, respectively. Measured BPSRTM_CORR values for the different subject groups 
are shown in figure 3C. No statistically significant differences were observed between 
groups. 
 
To investigate possible effects of intravascular activity on extracted cluster TAC, the 
correlation between cluster analysis BPPLASMA and Vb was investigated. In contrast to other 
results, all extracted clusters, except those representing tissue or cerebral spinal fluid, were 
included in this analysis. A scatter plot of cluster analysis BPPLASMA versus Vb is shown in 
figure 4. A large number of clusters (201 out of 390) were excluded because they resulted in 
unrealistic or unreliable BP or Vb values (BPPLASMA > 15 or its COV > 70%; Vb < 0, Vb > 
0.12 or its COV > 70%). Cluster TAC with low BPPLASMA tended to have high Vb and cluster 
TAC with high BPPLASMA tended to have low Vb. 
 
Table 1. Number of rejected fits. Number of rejected subjects for a specific ROI and model can be higher than the 
total number of rejected subjects as not all ROI were included in all comparisons. 
 
             
Group Model Total Rejected 
Unphys. 
clusters 
Cerebellum  Cerebrum 
Cluster 
anal. 
Gray Total White  Gray Total White 
      
       
Young BPPLASMA 10 4 3 0 0 0  0 0 0 1 
Elderly BPPLASMA 10 4 1 2 0 0  1 0 0 1 
MCI BPPLASMA 10 4 0 4 0 0  1 1 1 0 
AD BPPLASMA 9 3 0 2 2 2  1 1 1 1 
Young BPSRTM 10 5 3 2 1 1  1 1 2 1 
Elderly BPSRTM 10 2 1 0 1 1  0 2 5 1 
MCI BPSRTM 10 1 0 1 1 1  1 2 1 1 
AD BPSRTM 9 1 0 0 0 1  0 0 3 0 
Young BPSRTM_CORR 10 6 3 2 1 1  1 1 2 2 
Elderly BPSRTM_CORR 10 3 1 1 1 1  1 2 5 1 
MCI BPSRTM_CORR 10 5 0 5 1 1  2 2 2 1 
AD BPSRTM_CORR 9 2 0 2 2 3  1 1 4 1 
 
     
       
AD, Alzheimer’s disease; MCI, mild cognitive impairment; ROI, regions of interest. 
 
Evaluation of reference regions for (R)-[11C]PK11195 studies in Alzheimer's disease and mild cognitive impairment  
 
66 
Figure 2. Scatter plots of BPPLASMA (A and B) and BPSRTM (C and D) between cluster analysis and total cerebellum 
(A and C) or cerebrum gray matter (B and D). Data are shown for young (open circles), elderly (closed circles), MCI 
(closed triangles) and AD (open triangles) subjects. For BPPLASMA the regions mentioned are the fitted regions. For 
BPSRTM they are the reference regions used for fitting the thalamus TAC. 
 
Simulations 
 
Cluster analysis resulted in separation of areas with different BP and Vb (figure 5A-F). The 
algorithm was more sensitive to BP and to Vb changes (figure 5A). When the number of 
clusters used was higher than the number of areas with different kinetics, the simulated area 
with the lowest BP was separated into more than one cluster (Figure 5C and F). Similar ROI 
were extracted independent of noise level.   
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Figure 3. (A) BPPLASMA, (B) BPSRTM and (C) BPSRTM_CORR for young (black) elderly (hatched), MCI (grey) and AD 
(white) subjects. For BPPLASMA, the regions mentioned are the fitted regions, whereas for BPSRTM and BPSRTM_CORR 
they are the reference regions used for fitting the target TAC (thalamus). 
 
Figure 4. Scatter plot of cluster analysis BPPLASMA and Vb. Results are shown for all extracted clusters and for eight 
young (open circles), nine elderly (closed circles), 10 MCI (open triangles) and eight AD subjects (closed triangles). 
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Figure 5. Images of various clustered simulated volumes containing a region with increased BP (2.2, left inserted 
square) and a region with increased Vb (0.09, right inserted square) in a homogeneous background (BP = 1.5; Vb = 
0.06). Images are shown for data with 10 (A-C) and 15% (D-F) noise levels, clustered into two (A and D) and three 
(B and E) and four (C and F) clusters. 
 
Extraction of volume into two clusters resulted in the background cluster (i.e. the volume 
without the high BP and Vb region) corresponding to the cluster ROI with the lowest 
BPPLASMA. 
 
When the volume was clustered into three clusters, the reference region cluster corresponded 
to the simulated ROI containing the high Vb voxels. When the volume was extracted into 
four clusters, the smallest cluster in the background, which did not contain the high BP or 
high Vb voxels, was the cluster with lowest BPPLASMA. 
 
Because of nonspecific binding (BPPLASMA ~ 1.5), all BPSRTM values were scaled down by a 
factor of approximately 2.5. Considerable variation was observed in BPSRTM depending on 
the number of extracted clusters (figure 6A). BPSRTM appeared to be nearly independent of 
noise level when the number of extracted clusters was correct or too low, but variation up to 
40% was observed when the number of extracted clusters was higher than the number of 
different structures in the scan. BPSRTM was approximately 40% lower when three clusters 
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Figure 6. Results from simulations showing target ROI BPSRTM using the cluster analysis ROI as reference region 
(A) and cluster analysis ROI BPPLASMA (B) as function of noise level (5%, 10%, and 15%) for two (black), three 
(white) or four (gray) extracted clusters. 
 
were extracted instead of two. The BPPLASMA results showed a more negative bias as the 
number of extracted clusters and the noise level increased (figure 6B). 
 
 
Discussion 
 
The most important finding of this study is that BPSRTM and BPSRTM_CORR obtained with 
anatomic reference regions are linearly related to BPSRTM (R2 = 0.59 to 0.76) and BPSRTM_CORR 
(R2 = 0.83 to 0.86) obtained with the reference region defined by cluster analysis in controls 
and patients with MCI and AD (figure 2). On the basis of these relationships, the validity of 
using anatomic ROI and cluster analysis is similar, although performance differences exist 
which are reflected in different correlation coefficients for observed BPPLASMA and BPSRTM 
values (figure 2 and 3). These results confirm those of Cagnin and co-workers (Cagnin et al., 
2001b), who found high BPSRTM correlations (R2 = 0.94 to 0.96) when using either total 
cerebellum or cluster analysis as reference region in a healthy subject and a subject suffering 
from herpes encephalitis. 
 
Correlation coefficients observed between cluster analysis and cerebrum ROI BPPLASMA were 
high (R2 = 0.92 to 0.94) when using either total cerebellum or cluster analysis as reference 
region in a healthy subject and a subject suffering from herpes encephalitis. 
 
Correlation coefficients observed between cluster analysis and cerebrum ROI BPPLASMA were 
high (R2 = 0.92 to 0.94) compared with those obtained between cluster analysis and 
cerebellum ROI BPPLASMA (R2 = 0.52 to 0.68). Because all evaluated ROI were relatively 
large, differences in noise level are not responsible for this observed difference. Because the 
cluster analysis ROI will have more voxels in common with cerebrum ROI than with 
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cerebellum ROI, their TAC shapes will be more similar and therefore the higher correlation 
with cerebrum BPPLASMA is logical. This increased correlation, however, does not imply 
increased accuracy or precision. 
 
Differences in COV of BPPLASMA, BPSRTM and BPSRTM_CORR for the various reference regions 
were small. Because noise levels in TAC of all reference regions evaluated were also low, 
no distinction between ROI could be made in terms of precision. Better precision of BPSRTM 
was observed by Turkheimer and co-workers (Turkheimer et al., 2007), who showed that use 
of anatomically defined reference regions resulted in better test-retest variabilities of BPSRTM 
in target areas than those based on cluster analysis, even when using a cluster analysis with 
improved precision at the cost of decreased accuracy. 
 
Observed BPSRTM results using simulated clusters as reference region resulted in lower 
BPSRTM values for three clusters than for either two or four clusters. For three clusters, the 
extracted reference region cluster represented voxels with high Vb, which resulted in a 
negative bias in BPSRTM values (simulations, data not shown). Selection of voxels on the basis 
of Vb differences may occur, which can lead to a cluster analysis reference region with biased 
BP, also because a correlation was observed between Vb and BP (figure 4). 
 
The cluster analysis resulted in rejection of 10% of the scans evaluated. Banati and co-
workers (Banati et al., 2000, Cagnin et al., 2001a) used comparison of extracted cluster TAC 
with a database of normal cluster TAC and rejected TAC according to dissimilarity. It is not 
clear whether this criterion would have selected the same scans for rejection. Unfortunately, 
Banati and co-workers did not mention the number of rejected scans. Furthermore, the 
distribution of voxels over the various clusters in the present study was significantly different 
from that previously reported. Banati and coworkers (Banati et al., 2000) found that the two 
largest clusters contained 90% of the voxels. In the present study, the cluster volume 
decreased from 27 ± 4% of the voxels towards 1 ± 0.3% of the voxels, with the largest cluster 
representing skull in most of the cases. These differences may be related to differences in 
scanner characteristics, reconstruction algorithm, scatter correction or differences in 
shielding for out of field of view scatter. 
 
From a physiologic point of view, the cerebellum is affected in a more advanced stage of AD 
than the cerebrum and should therefore be preferred (Braak and Braak, 1991). In general 
(R)-[11C]PK11195 binding is assumed to be absent in normal brain (Banati et al., 2000), 
except in the thalamus of healthy elderly controls (Cagnin et al., 2001a). In addition, it is 
assumed that increased BP reflects activation of microglia. Clearly, any dissociation between 
total (R)-[11C]PK11195 uptake and binding to activated microglia between regions and / or 
subject groups would complicate physiologic interpretation of BP results. This is, however, 
unlikely as a histologic study (Banati et al., 2000) has shown that (R)-[11C]PK11195 binds to 
activated microglia and not to other cells. Finally, it is assumed that labeled metabolites do 
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not cross the blood-brain barrier. At least for mice this has been confirmed (Dumont et al., 
1999). 
In summary, apart from the high number of unrealistic BPSRTM results using the cerebellum 
white matter, total cerebellum or cerebrum white matter as reference region, only small 
differences in reference region performance were observed. Total cerebellum, however, is 
the best choice, as it correlates well with other reference region BP, results in low numbers 
of unrealistic BPSRTM values and is likely to have specific binding only in a late state of the 
disease process. In addition, in contrast to cluster analysis, it does not have noise-induced 
bias and rejection of 10% of the scans. 
 
At present there is increased interest in in vivo imaging of inflammatory processes. A number 
of alternative ligands for the peripheral benzodiazepine receptor are under investigation, such 
as DAA1106 (Maeda et al., 2004, Ikoma et al., 2007) and vinpocetine (Gulyas et al., 2002a, 
2002b, 2002c, 2005). Although initial results are promising in that uptake of these ligands in 
brain is higher than that of (R)-[11C]PK11195, there is a need for full quantitative comparative 
studies. It is likely that results of the present study are also relevant for these new ligands, as 
they target the same receptor. 
 
 
Conclusion 
 
BP values of (R)-[11C]PK11195 scans in normal subjects and MCI and AD patients are 
similar when total cerebellum or cluster analysis are used as reference regions. Total 
cerebellum is the reference region of choice, because cluster analysis fails in approximately 
10% of cases. 
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Abstract 
 
Inflammatory mechanisms, like microglial activation, could be involved in the pathogenesis 
of Alzheimer's disease (AD). (R)-[11C]PK11195 (1-(2-chlorophenyl)-N-methyl-N-1(1-
methylpropyl)-3-isoquinolinecarboxamide), a positron emission tomography (PET) ligand, 
can be used to quantify microglial activation in vivo. The purpose of this study was to assess 
whether increased (R)-[11C]PK11195 binding is present in AD and mild cognitive 
impairment (MCI), currently also known as “prodromal AD.” Nineteen patients with 
probable AD, 10 patients with prodromal AD (MCI), and 21 healthy control subjects were 
analyzed. Parametric images of binding potential (BPND) of (R)-[11C]PK11195 scans were 
generated using receptor parametric mapping (RPM) with supervised cluster analysis. 
Differences between subject groups were tested using mixed model analysis, and associations 
between BPND and cognition were evaluated using Pearson correlation coefficients. Voxel-
wise statistical parametric mapping (SPM) analysis showed small clusters of significantly 
increased (R)-[11C]PK11195 BPND in occipital lobe in AD dementia patients compared with 
healthy control subjects. Regions of interest (ROI)-based analyses showed no differences, 
with large overlap between groups. There were no differences in (R)-[11C]PK11195 BPND 
between clinically stable prodromal AD patients and those who progressed to dementia, and 
BPND did not correlate with cognitive function. Microglial activation is a subtle phenomenon 
occurring in AD. 
 
 
Introduction 
 
Alzheimer's disease (AD) is a neurodegenerative disorder, clinically characterized by 
progressive cognitive decline and impaired execution of daily activities (McKhann et al., 
1984). Patients with mild cognitive impairment (MCI) have documented memory impairment 
but are still able to perform daily activities in a normal manner. MCI is considered to be a 
transitional phase between normal aging and AD (Petersen et al., 1999). Subjects with MCI 
have an increased risk of developing clinical AD of about 12% per year compared with 1%-
2% in the general population (Petersen, 2004). Recently, new criteria for the diagnosis related 
to neuropathological changes in AD, based on the use of biomarkers of AD (Dubois et al., 
2010). According to this new classification, patients with MCI are considered to have 
“prodromal AD.” 
 
AD is characterized histopathologically by intracellular neurofibrillary tangles (NFT), 
extracellular deposits of amyloid in senile plaques, and diffuse loss of neurons (Braak and 
Braak, 1991). Although not a pathological hallmark specific to AD, activated microglia 
invariably are found in AD, and they may be present years before symptoms become apparent 
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clinically (Peterson et al., 2006). Indeed, activated microglia could be an important 
therapeutic target, as microglial activation may be directly involved in the neurodegenerative 
process associated with AD (Yoshiyama et al., 2007). 
 
Microglial activation can be quantified in vivo using positron emission tomography (PET) 
and (R)-[11C]PK11195. The compound (R)-[11C]PK11195 (1-(2-chlorophenyl)-N-methyl-N-
(1-methylpropyl)-3-isoquinolinecarboxamide) is a highly specific ligand for the peripheral 
benzodiazepine-binding site (PBR). This site, also called the translocator protein 
(Papadopoulos et al., 2006), is expressed by cells of the mononuclear macrophage lineage 
and is markedly increased in activated microglia. Using (R)-[11C]PK11195 and PET, 
microglial activation has already been demonstrated in several neurodegenerative diseases 
(Venneti et al., 2006). In AD, increased (R)-[11C]PK11195 binding has been found in several 
brain areas (Cagnin et al., 2001, Yokokura et al., 2011). Recently, there have been two reports 
on (R)-[11C]PK11195 binding in MCI (Okello et al., 2009, Wiley et al., 2009). In both studies, 
(R)-[11C]PK11195 binding was assessed in two cohorts on MCI patients, being 11C-labeled 
Pittsburgh compound B ([11C]-PIB)-positive and -negative patients. These studies found 
either increased (Okello et al., 2009) or unchanged (Wiley et al., 2009) (R)-[11C]PK11195 in 
MCI. 
 
The purpose of the present study was to further investigate the extent and distribution of 
(R)-[11C]PK11195 binding in larger cohorts of AD dementia and prodromal AD patients. A 
second aim was to establish whether presence of activated microglia in prodromal AD is 
associated with progression to AD dementia. 
 
 
Methods 
 
Subjects 
 
Twenty patients with probable AD, 13 patients with MCI, and 21 healthy control subjects 
were included. Patients were recruited from the outpatient clinic of the Alzheimer center at 
the VU University Medical Centre. All patients underwent standardized clinical assessment, 
including neurological and physical examinations, laboratory screening tests (including 
cerebrospinal fluid measures of amyloid β (Aβ), tau and tau phosphorylated at threonine-181 
(Bouwman et al., 2010), electroencephalogram (EEG), magnetic resonance imaging (MRI), 
and neuropsychological examination. Final diagnosis was established at a multidisciplinary 
consensus meeting. Diagnosis of probable AD was based on National Institute of 
Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related 
Disorders Association (NINCDS-ADRDA) criteria (McKhann et al., 1984), and diagnosis of 
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MCI on Petersen criteria (Petersen et al., 1999). Subjects underwent a standard battery of 
examinations, including history taking, medical and neurological examination, and 
neuropsychological examination, which consisted of the New York University Recall Test 
(NYU), Rey's Auditory Verbal Learning Test (RAVLT), Trail Making Test A and B, 
Fluency, Rey's complex figure, Boston Naming Test, and forward and backward condition 
of the Digit Span. 
 
According to recently proposed criteria for prodromal AD (Dubois et al., 2010), MCI and 
AD patients were excluded from the analysis if there was no medial temporal lobe atrophy 
(MTA) or no abnormal cerebrospinal fluid profile (Bouwman et al., 2010) (one MCI patient). 
Consequently, MCI will be reported as prodromal AD. For clinical follow-up, prodromal AD 
patients visited the memory clinic annually. One patient progressed to dementia with Lewy 
bodies and was excluded from the analysis. 
 
Control subjects without cognitive complaints were recruited by advertisement in local 
newspapers. All control subjects underwent the same diagnostic procedure (except EEG and 
lumbar puncture). Control subjects had to have age-corrected normal scores on 
neuropsychological assessments and a normal MRI (including MTA scores) (Bouwman et 
al., 2010), which was evaluated by a neuroradiologist. 
 
Exclusion criteria for all subjects were known major psychiatric illness, previous head trauma 
with loss of consciousness of more than 1-hour duration, any significant metabolic disorder, 
and alcohol or substance abuse according to the Diagnostic and Statistical Manual of Mental 
Disorders-IV (DSM-IV) criteria (American Psychiatric Association, 2000). Intake of 
benzodiazepines, antipsychotic drugs, and non-steroidal anti-inflammatory drugs was not 
allowed because of possible interaction with (R)-[11C]PK11195 binding. Written informed 
consent was obtained from all participants and in case of patients with AD also from a next 
of kin. The study protocol was approved by the Medical Ethics Review Committee of the VU 
University Medical Centre. 
 
MRI 
 
All subjects had a structural MRI scan within 4 months of the PET procedure. MRI scans 
were acquired using a 1.0-T scanner (Magnetom IMPACT, Siemens Medical Solutions, 
Erlangen, Germany) and included a 3D heavily T1-weighted gradient echo sequence 
(magnetization prepared rapid acquisition gradient echo). Voxel size of the MRI images was 
0.98 x 0.98 x 1.49 mm3. These scans were used both for segmentation of grey and white 
matter and for delineation of regions of interest (ROI). 
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Production of (R)-[11C]PK11195 
 
(R)-[11C]PK11195 was produced according to published methods (Shah et al., 1994). Each 
(R)-[11C]PK11195 injection solution met the following pharmaceutical specifications: 
specific activity (SA) > 18.5 GBq∙μmol-1; radiochemical purity > 98%; 5 < pH < 8.  
 
PET 
 
PET scans were acquired using an ECAT EXACT HR+ (Siemens/CTI, Knoxville, TN, USA) 
(Brix et al., 1997). First, a 10-minute transmission scan was performed in 2D acquisition 
mode using three retractable rotating line sources. This scan was used to correct the 
subsequent emission scan for photon attenuation. Then, a 3D dynamic (R)-[11C]PK11195 
emission scan was performed consisting of 22 frames with progressive increase in frame 
duration (1 x 30 background, 1 x 15, 1 x 5, 1 x 10, 2 x 15, 2 x 30, 3 x 60, 4 x 150, 5 x 300 
and 2 x 600 seconds; total acquisition time 60.5 minutes). Detailed scanning procedures have 
been described previously (Mourik et al., 2010, Schuitemaker et al., 2007a, 2012). Subject 
motion during scanning was checked visually at regular intervals (by checking the position 
of the head using laser beams) and corrected immediately, if necessary. 
 
Image reconstruction 
 
All PET sinograms were corrected for dead time, tissue attenuation using the transmission 
scan, decay, scatter, and randoms. Data were reconstructed using a filtered back projection 
(FBP) reconstruction algorithm (Ollinger and Fessler, 1997), as well as a partial volume-
corrected (PVC) ordered subset expectation maximization (OSEM) reconstruction algorithm 
that incorporates the scanner's point spread function in the system matrix during 
reconstruction. This PVC-OSEM algorithm has been validated previously. For PVC-OSEM, 
4 iterations with 16 subsets and no loop or postfilter were used (Hudson and Larkin, 1994). 
Reconstructed images were filtered using a Hanning filter of 5 mm full width at half 
maximum (FWHM), both in transaxial and axial directions. A zoom factor of 2 and a matrix 
size of 256 x 256 x 63 were used, resulting in a voxel size of 1.2 x 1.2 x 2.4 mm3 and a spatial 
resolution of approximately 2.5-mm full width at half maximum in the center of the field of 
view. Images were then transferred to workstations (Sun Microsystems, Santa Microsystems, 
Santa Clara, CA, USA) for further analysis. One AD and one prodromal AD patient were 
excluded because of insufficient quality of the PET scans for regional analysis (movement 
artifacts). 
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Data analysis 
 
Parametric images of binding potential (BPND) of (R)-[11C]PK11195 were generated using 
receptor parametric mapping (RPM, Gunn et al., 1997), A basis function implementation of 
the simplified reference tissue model (SRTM) (Lammertsma and Hume, 1996). RPM was 
found to be the most suitable parametric method for analysis of (R)-[11C]PK11195 data 
(Schuitemaker et al., 2007a). Supervised cluster analysis was used to extract the reference 
tissue input curve directly from the dynamic (R)-[11C]PK11195 data (Turkheimer et al., 
2007). The primary outcome measure was BPND (Innis et al., 2007, Lammertsma and Hume, 
1996). 
 
Regions of interest definition 
 
For each subject, PET and MRI scans were coregistered using the software package MIRIT 
(Maes et al., 1997, West et al., 1997). ROI were drawn manually on bilateral hippocampus, 
amygdala, entorhinal cortex, and lateral and superior temporal lobe using the software 
program DISPLAY, developed at the McConnell Brain Imaging Centre (BIC) of the 
Montreal Neurological Institute, McGill University (available at the site 
www.bic.mni.mcgill.ca/ ServicesSoftwareVisualization/HomePage). ROIs were drawn 
manually by a trained researcher (A.S.) on the individual MRI scans in a plane by plane 
fashion according to anatomical structures. These 2D ROI can be defined in transaxial, 
coronal, and sagittal planes, and these orientations used for ROI definition could be changed 
anytime throughout the manual delineation process, thereby facilitating generations of 3D 
ROI. In addition, template ROIs were defined using probability map-based automatic brain 
delineation (Svarer et al., 2005). ROIs in this template include the frontal, orbital frontal, and 
medial inferior frontal cortex), cingulate posterior cortex, thalamus, parietal cortex, and 
occipital cortex. Regional values of BPND were obtained by projecting the manual and 
template ROIs, defined above, onto the parametric BPND images. 
 
Statistical analysis 
 
Statistical analysis of ROI data were performed using SPSS software (SPSS Institute, 
Chicago, IL, USA), version 15.0. Values are presented as mean ± standard deviation (SD). 
Differences in clinical characteristics, tracer doses, and specific activity between different 
subject groups were tested using analysis of covariance (ANCOVA) with post hoc Bonferroni 
corrections and age as a covariate. A linear mixed model was used to assess group differences 
in regional binding. Mixed models use all data available from all cortical regions, properly 
account for within-person correlations over the different cortical regions, and appropriately 
handle missing data. The model included diagnosis, region, and interaction of diagnosis and 
region. Age was used as a covariate, and BPND was the dependent variable. The threshold for 
significance was set at p < 0.05. Analyses were repeated with prodromal AD and AD 
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combined as one patient group and compared with healthy control subjects. Associations 
between (R)-[11C]PK11195 binding and cognitive test results were evaluated using Pearson 
correlation coefficient adjusted for multiple comparisons. 
 
Voxel-wise analysis 
 
Voxel-wise analysis of parametric BPND images was performed using statistical parametric 
mapping (SPM) (SPM2; www.fil.ion.ucl.ac.uk/spm). The purpose of this analysis was to 
assess whether there were clusters of voxels with altered binding that could not be identified 
in the ROI analysis, for example due to heterogeneity within and across ROIs. As voxel-wise 
analysis is very sensitive to patient movement, scans were checked visually for motion 
artifacts prior to SPM analysis. Standard additional smoothing within SPM using a 10-mm 
full width at half maximum Gaussian filter was performed to reduce noise to acceptable levels 
and to obtain sufficient overlap of structures between subjects for SPM analysis. Differences 
between AD dementia or prodromal AD patients (and subgroups of [non]converters) and 
healthy control subjects were assessed in a voxel-wise comparison, using two sample t tests. 
SPM analyses were performed without proportional scaling. Proportional scaling can be 
omitted because RPM plots are quantitatively accurate even at low noise levels, as shown 
previously (Schuitemaker et al., 2007b). SPM results were thresholded at both p < 0.01 and 
p < 0.001. The false discovery rate method to correct for multiple comparisons within SPM 
was used to provide corrected p-values (Genovese et al., 2002). 
 
 
Results 
 
Demographic and clinical data 
 
Baseline characteristics of participants, eligible for analysis, are presented in Table 1. There 
were no differences in age or gender between AD patients, prodromal AD patients, and 
healthy control subjects. MTA score was lower in healthy control subjects compared with 
prodromal AD or AD dementia patients. AD dementia patients had lower Mini-Mental State 
Examination (MMSE) scores (Folstein et al., 1975) than healthy control subjects and 
prodromal AD patients, and scores in prodromal AD patients were lower than those in healthy 
control subjects. AD dementia patients and prodromal AD patients had lower scores on the 
NYU paragraph recall test, the RAVLT, and the backwards condition of the digit span 
compared with control subjects. AD dementia patients had higher scores on the trail making 
test A compared with control subjects and prodromal AD, and on the trail making test B 
compared with control subjects. Seven of the 10 prodromal AD patients progressed clinically 
and fulfilled AD dementia criteria at follow-up. Three patients remained clinically stable until 
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they were lost to follow up (mean follow-up duration was 2.7 ± 0.6 years; range, 2.3-3.3 
years). Prodromal AD patients who converted to AD dementia had higher scores on the 
forward condition of the digit span than patients who did not convert (6.3 vs. 4.7; p = 0.011). 
Otherwise, there were no differences in cognitive test results at baseline between converters 
and nonconverters (p ≥ 0.05). 
 
Table 1. Subject characteristics. 
 
    
 Controls Prodromal AD AD 
N 21 10 19 
Age (years) 68 ± 8 72 ± 6 69 ± 8 
Sex M : F 13 : 8 7 : 3 11 : 8 
MTA score 0.3 ± 0.4 1.3 ± 0.6 1.5 ± 0.9 
MMSEa, b, c 29 ± 1 26 ± 1 23 ± 3 
NYU test scorea, b 9.2 ± 4.2 3.9 ± 1.7 1.3 ± 1.9 
RAVLTa, b 8.6 ± 3.2 2.1 ± 2.2 0.4 ± 0.7 
Trail Ab, c 43 ± 12 46 ± 14 71 ± 22 
Trail Bb 89 ± 34 139 ± 68 190 ± 87 
Digit forward 6.4 ± 0.9 5.8 ± 1.0 6.1 ± 1.0 
Digit backwarda, b 5.7 ± 1.1 3.7 ± 0.5 4.5 ± 1.2 
 
   
Data are presented as mean ± S.D. Key: AD, Alzheimer's disease; MTA score, mean medial temporal lobe atrophy; 
MMSE, Mini-Mental State Examination; NYU, New York University paragraph recall test; RAVLT, Rey's Auditory 
Verbal Learning Test; Trail A and B, trail making test A and B; Digit forward and backward, forward and backward 
condition of the digit span. a p < 0.05 for controls vs. prodromal AD;.b p < 0.05 for controls vs. AD; c p < 0.05 for 
prodromal AD vs. AD. 
 
(R)-[11C]PK11195 administration 
 
There were no differences in injected tracer dose or specific activity between subject groups. 
Mean tracer dose was 350 ± 102, 295 ± 159, and 303 ± 87 MBq (F(2,45) = 1.14, p = 0.44), 
and mean specific activity was 79 ± 36, 84 ± 41, and 92 ± 35 GBq∙μmol-1 (F(2,47) = 0.62, p 
= 0.54) in AD dementia patients, prodromal AD patients, and healthy control subjects, 
respectively. Estimated receptor occupancy associated with these high SA tracer doses was 
< 1%. 
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ROI analysis 
 
In Table 2, RPM-derived BPND values of (R)-[11C]PK11195 are shown for different regions 
in AD dementia patients, prodromal AD patients, and healthy control subjects, using the 
standard FBP reconstruction algorithm. Linear mixed models showed no significant main 
effect of diagnostic group (p = 0.53). There was an effect of brain region (p < 0.001). No 
interaction was found (p = 0.11), indicating that regional differences were similar across 
diagnostic groups. This is also illustrated in figure 1, showing BP values in the different 
subject groups. In general, BPND was highest in frontal lobe, posterior cingulate cortex, 
thalamus, pariental, and occipital lobes. Results were similar (main effect of brain region [p 
< 0.001], but no main effect of diagnostic group [p = 0.93] and no interaction [p = 0.13]) 
when images with higher spatial resolution, as obtained with the PVC-OSEM reconstruction 
algorithm, were used. 
 
When the analyses were repeated, with prodromal AD and AD dementia combined as one 
patient group, comparable results were obtained. 
 
Table 2. Regional values of (R)-[11C]PK11195 BPND. 
 
    
ROIs Controls Prodromal AD AD 
    
Frontal 0.182 ± 0.101 0.202 ± 0.128 0.231 ± 0.127 
Cingulate posterior 0.370 ± 0.133 0.387 ± 0.142 0.338 ± 0.172 
Lateral temporal 0.054 ± 0.094 0.067 ± 0.111 0.079 ± 0.108 
Superior temporal 0.132 ± 0.141 0.136 ± 0.167 0.177 ± 0.092 
Amygdala 0.103 ± 0.171 0.167 ± 0.193 0.054 ± 0.167 
Hippocampus 0.049 ± 0.112 0.032 ± 0.207 0.014 ± 0.120 
Entorhinal 0.156 ± 0.145 0.080 ± 0.240 0.047 ± 0.176 
Thalamus 0.234 ± 0.090 0.279 ± 0.168 0.311 ± 0.182 
Parietal 0.202 ± 0.124 0.234 ± 0.156 0.199 ± 0.134 
Occipital 0.439 ± 0.108 0.462 ± 0.054 0.427 ± 0.144 
 
   
Data are presented as mean ± S.D. Key: ROIs, regions of interest; AD, Alzheimer's disease. 
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Figure 1. (R)-[11C]PK11195 BPND in healthy control subjects, prodromal Alzheimer's disease (AD) and AD 
dementia patients. Filled diamonds indicate controls, filled squares indicate patients with prodromal AD who 
remained clinically stable, open squares indicate patients with prodromal AD who progressed to dementia, and filled 
triangles indicate AD dementia patients. 
 
Voxel-wise analysis 
 
Voxel-wise analysis of BPND images showed increased (R)-[11C]PK11195 binding in AD 
dementia patients compared with healthy control subjects in bilateral occipital cortex (p = 
0.01) (figure 2). At a higher statistical threshold (p = 0.001), no increased signal was found. 
No differences in (R)-[11C]PK11195 binding between prodromal AD patients (and 
subgroups) and healthy control subjects or AD dementia patients were found. When the 
analyses were repeated with prodromal AD patients and AD dementia patients as one group 
and compared with healthy control subjects, no differences were found. 
 
(R)-[11C]PK11195 binding potential and cognition 
 
There were no correlations with cognitive tests at baseline and (R)-[11C]PK11195 BPND in 
any region. There was no difference in BPND between prodromal AD patients who remained 
clinically stable and those who progressed clinically to dementia. 
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Figure 2. Regions with increased (R)-[11C]PK11195 BPND in Alzheimer's disease dementia compared with healthy 
control subjects. Images were thresholded at p = 0.01. Extent threshold = 10 voxels. The color bar indicates T values. 
Data were corrected for multiple comparisons using the false discovery rate method within SPM. 
 
Discussion 
 
In this study, only small clusters of increased (R)-[11C]PK11195 binding were found in 
bilateral occipital lobe in AD dementia patients using voxel-based analysis. ROI-based 
analyses showed no differences between diagnostic groups, with large overlap between 
subject groups. This suggests that microglial activation in AD is a subtle phenomenon, which 
is present in AD dementia. 
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Quantification of (R)-[11C]PK11195-specific binding (BPND) was performed using RPM 
(Schuitemaker et al., 2007a) and a modified supervised cluster analysis (Boellaard et al., 
2008, Turkheimer et al., 2007, Yaqub et al., 2009) to extract the reference tissue input curve. 
Given the relatively low specific signal in AD and especially prodromal AD, it is essential to 
use optimal methodology. For quantification, use of a pure enantiomer, in this case 
(R)-[11C]PK11195, is mandatory (Shah et al., 1994). In addition, it has been shown that in 
pathological conditions like AD, with reduced flow rates or variation in blood volume, a basis 
function method is preferred above other simplified methods, such as standardized uptake 
values (Hoekstra et al., 2000) or Logan plot analysis (Logan et al., 1990, 1996), for analyzing 
(R)-[11C]PK11195 data because it produces less bias and is more precise (Schuitemaker et 
al., 2007a). As such, RPM with an optimized supervised cluster analysis to extract the 
reference tissue curve was used in this study. 
 
The present findings are largely in agreement with previous (R)-[11C]PK11195 studies in AD, 
in which cluster (Cagnin et al., 2001) or supervised cluster analysis methods (Edison et al., 
2008) were used to derive the reference region and in which also subtle increased 
(R)-[11C]PK11195 binding was demonstrated. To date, two (R)-[11C]PK11195 studies in MCI 
patients have been reported (Okello et al., 2009, Wiley et al., 2009). In both studies, 
(R)-[11C]PK11195 binding was examined in [11C]PIB-positive and -negative patients, where 
[11C]PIB was used as a biomarker of disease severity. Wiley et al. reported (R)-[11C]PK11195 
binding in cerebellum, mesial temporal cortex, sensorimotor cortex, frontal cortex, parietal 
cortex, and posterior cingulate cortex but did not demonstrate significant differences between 
diagnostic groups, comparable with the present results. Okello et al. did demonstrate 
increased (R)-[11C]PK11195 binding in the frontal cortex in a small group of [11C]PIB 
positive patients, although no correlations between amyloid depositions, as measured with 
[11C]PIB, and (R)-[11C]PK11195 binding in frontal cortex were found. 
 
In the present study, only patients with the most common subtype of MCI, amnestic MCI, 
currently defined as prodromal AD (Dubois et al., 2010, Petersen et al., 1999), were included. 
Neuropathological data indicate that many amnestic MCI patients have already high numbers 
of plaques and tangles (Morris et al., 2001, Petersen et al., 2006, Price and Morris, 1999), 
especially in the medial temporal lobe (Petersen et al., 2006, Price and Morris, 1999), as has 
been acknowledged in the new proposed criteria for AD, in which patients with biomarker-
positive amnestic MCI are considered to have a predementia stage of AD (prodromal AD, 
Dubois et al., 2010). This is in agreement with postmortem studies demonstrating that 
activation of microglia precedes neurodegenerative changes in the neocortex (Rozemuller et 
al., 1989, Veerhuis et al., 2003). Indeed, a gradual increase of microglial activation with 
increasing Braak scores of neurofibrillary changes and with Congo red-positive deposits has 
been reported (Arends et al., 2000, Hoozemans et al., 2005). As clinicopathological and 
animal studies have demonstrated that microglia are attracted to the site of amyloid plaque 
formation (Arends et al., 2000, Meyer-Luehmann et al., 2008), one could expect increased 
(R)-[11C]PK11195 binding in regions with reported Aβ deposition. Consequently, one might 
expect increased (R)-[11C]PK11195 binding in prodromal AD patients, who progress to AD 
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dementia, but also even earlier in preclinical AD. In this context, regional increases in 
(R)-[11C]PK11195 binding in prodromal AD might reflect early changes, associated with Aβ 
deposition, occurring before structural changes can be seen. However, no differences in 
(R)-[11C]PK11195 binding were found between prodromal AD patients who stayed stable 
and those who progressed to dementia. 
 
Moreover, although some trends were observed, none of the observed correlations between 
cognitive scores at baseline and (R)-[11C]PK11195 BPND in any of the brain regions in 
prodromal AD or AD dementia patients were significant after correction for multiple 
statistical comparisons. Previously, Yokokura et al. (Yokokura et al., 2011) examined 
(R)-[11C]PK11195 binding as well as [11C]PIB and glucose metabolism in a relatively small 
group of AD patients and demonstrated a correlation between (R)-[11C]PK11195 binding and 
MMSE scores in AD. Okello et al. (Okello et al., 2009) also explored correlations between 
(R)-[11C]PK11195 binding and cognition in a small group of MCI patients and reported no 
correlations between (R)-[11C]PK11195 binding and MMSE in PIB-positive MCI patients, 
which is in agreement with the present results. Because the sample size was relatively small 
and the follow-up period relatively short, a larger study is needed to confirm these findings. 
Furthermore, to assess (R)-[11C]PK11195 binding in the earliest stages of AD, it would also 
be interesting to study asymptotic-at-risk or presymptomatic AD subjects (Dubois et al., 
2010). 
 
Remarkably, ROI-based analyses showed relatively low regional binding in the medial 
temporal lobe regions (figure 1). Relatively low BPND might be caused by partial volume 
effects, especially in relatively small regions surrounded by cerebrospinal fluid, such as 
hippocampus and entorhinal cortex, or by a relatively higher binding in the reference region 
than that in the target region. To limit partial volume effects, a novel PVC-OSEM 
reconstruction algorithm was also applied, but this did not affect results. An alternative 
explanation could be that within an ROI, a relatively smaller region shows increased 
(R)-[11C]PK11195 binding. As such, averaging all voxels within a predefined ROI may dilute 
a potential signal in part of that ROI and could therefore lead to false-negative findings. This 
might also explain the differences between voxel-based and ROI-based methods, as voxel-
based methods do not suffer from this “dilution” effect. 
 
The present results, describing only small areas with increased (R)-[11C]PK11195 binding, 
suggest that microglia activation in AD is a subtle phenomenon. An important question is 
whether microglial activation plays a harmful or beneficial role in the development of AD. 
The function of microglia in the brain is twofold. In normal brain tissue, they survey the brain 
environment and when structural or functional integrity of the brain is threatened they 
transform to activated states. When activated, microglia can have both neuroprotective and 
neurotoxic roles (Akiyama et al., 2000). As such, it is possible that activated microglia may 
induce neuronal damage. In AD, microglial activation occurs around neuritic plaques, where 
it may be involved in the degradation and phagocytosis of Aβ deposits (Akiyama et al., 2000). 
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This could constitute a beneficial effect of microglia activation. Activated microglia, 
however, are also present in areas with low amyloid load, indicating that other mechanisms 
than plaque formation appear to contribute to microglial activation (DiPatre and Gelman, 
1997) . Indeed, in an animal model of AD, microglial activation and loss of synapses 
preceded tangle formation (Yoshiyama et al., 2007), suggesting that microglial activation and 
neuronal damage are closely connected. Although preclinical studies do not provide 
conclusive evidence for either a neuroprotective or neurotoxic role of activated microglia in 
AD, converging data indicate that “inflammatory processes may be a driving force of the 
pathology associated with AD” (Wyss-Coray, 2006). As such, neuroprotective strategies 
targeted at reducing microglial activity may be beneficial not only in AD dementia, but also 
in prodromal AD. If microglial activation is a causative factor for neuronal degeneration, it 
could be an important target for treatment of age-related cognitive problems. Imaging of 
microglial activation can contribute to better understanding of the role of inflammation in 
AD. It might be useful to monitor the effect of future preventive and therapeutic treatments 
in clinical trials. 
 
In conclusion, small clusters of increased (R)-[11C]PK11195 binding were found in AD 
patients but not in prodromal AD subjects, indicating that microglial activation may 
contribute to better understanding of the role of inflammation in AD. 
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Abstract 
 
Rheumatoid arthritis (RA) involves migration of macrophages into inflamed areas. 
(R)-[11C]PK11195 binds to peripheral benzodiazepine receptors, expressed on macrophages, 
and may be used to quantify inflammation using positron emission tomography (PET). This 
study evaluated methods for the quantification of (R)-[11C]PK11195 binding in the knee of 
RA patients. Data from six patients with RA were analyzed. Dynamic PET scans were 
acquired in 3-D mode following (R)-[11C]PK11195 injection. During scanning arterial 
radioactivity concentrations were measured to determine the plasma (R)-[11C]PK11195 
concentrations. Data were analyzed using irreversible and reversible one-tissue and two-
tissue compartment models and input functions with various types of metabolite correction. 
Model preferences according to Akaike information criterion (AIC) and correlations between 
measures were evaluated. Correlations between distribution volume (Vd) and standardized 
uptake values (SUV) were evaluated. AIC indicated optimal performance for a one-tissue 
reversible compartment model including blood volume. High correlations were observed 
between Vd obtained using different input functions (R2 = 0.80 - 1.00) and between Vd 
obtained with one- and two-tissue compartment models (R2 = 0.75 - 0.94). A high correlation 
was observed between optimal Vd and SUV after injection (R2 = 0.73). The 
(R)-[11C]PK11195 kinetics in the knee were best described by a reversible single-tissue 
compartment model including blood volume. Applying metabolite corrections did not 
increase sensitivity. Due to the high correlation with Vd, SUV is a practical alternative for 
clinical use. 
 
 
Introduction 
 
Rheumatoid arthritis (RA) is an inflammatory autoimmune disorder of the joints. It involves 
loss of bone and cartilage and inflammation of the synovium. Various studies have been 
performed to investigate the usefulness of PET using 18F labeled fluorodeoxyglucose (FDG) 
for diagnosis of RA (Ju et al., 2008, Elzinga et al., 2007, Blockmans et al., 2007, Beckers et 
al., 2004). As RA is an inflammatory disease, tracers that bind to the peripheral 
benzodiazepine receptor (PBR), also called omega-3 receptor, which is expressed on 
macrophages, may be of even more interest. 
 
The compound (R)-PK11195 [(R)-1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-
isoquinoline carboxamide] is a ligand that binds to the PBR receptor and can therefore be 
used as a marker of inflammation. The latter has been demonstrated in both in vitro (Zavala 
and Lenfant, 1987) and in vivo (Jones et al., 2002) studies. When labeled with 11C, 
(R)-[11C]PK11195 concentrations in the body can be quantified using positron emission 
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tomography (PET). In the brain, (R)-[11C]PK11195 binds to activated microglia (Banati et 
al., 2000) which are part of the brains immune system. (R)-[11C]PK11195 has been used 
extensively to image brain inflammation using PET (Price et al., 2006, Chen and Guilarte, 
2006, Iversen et al., 2006, Gerhard et al., 2006, Cagnin et al., 2006, Hammoud et al., 2005, 
Versijpt et al., 2005, Ouchi et al., 2005, Henkel et al., 2004). Methods have been published 
regarding the quantification of (R)-[11C]PK11195 binding in the brain (Schuitemaker et al., 
2007, Kropholler et al. 2005, 2006). A limited number of studies have been performed in 
other organs, such as the lung (Jones et al., 2002, 2003, 2005, Hardwick et al., 2005) and the 
heart (Charbonneau et al., 1986). 
 
To use PET with the tracer (R)-[11C]PK11195 as a research tool for RA inflammation, a 
methodology for quantification of (R)-[11C]PK11195 binding in inflamed knee joints in RA 
using PET has to be available. The purpose of this study was to develop such methodology. 
 
 
Materials and methods 
 
Patients 
 
Nine patients (three male, age 54 ± 8 years) were included in the study. Patients were 
diagnosed with RA according to the criteria of the American College of Rheumatology 
(Felson et al., 1993, 1995). For each patient, inflammation was present in at least one knee. 
The study was approved by the medical ethics committee of the VU University Medical 
Center. All patients gave informed consent prior to inclusion. 
 
Scanning protocol 
 
Scans were performed in 3-D acquisition mode using an ECAT EXACT HR+ (CTI/Siemens, 
Knoxville, TN) PET scanner (Brix et al., 1997, Adam et al., 1997). All patients underwent a 
1-hr dynamic (R)-[11C]PK11195 scan of the knee region with progressively increasing frame 
durations (one 15 s, one 5 s, one 10 s, two 15 s, three 60 s, four 150 s, five 300 s and two 600 
s). A bolus of 490 ± 120 MBq (R)-[11C]PK11195 with specific activity higher than 18.5 
GBq/μmol at the end of synthesis was injected at the start of the scan. During the scan, arterial 
radioactivity concentration was monitored continuously using a blood sampler device 
described previously (Boellaard et al., 2001). In addition, at set times (3, 5, 10, 20, 30, 40 and 
60 min after injection), continuous withdrawal was interrupted briefly to collect discrete 
arterial samples. These samples were used to determine plasma/whole blood radioactivity 
concentration ratios and radioactivity concentrations of (R)-[11C]PK11195 and metabolites. 
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Briefly, plasma was processed using solid-phase extraction to separate (R)-[11C]PK11195 
and its nonpolar metabolites were then processed using high-performance liquid 
chromatography to determine radioactivity concentrations (Greuter et al., 2005). 
 
Image reconstructions 
 
All emission scans were normalized and corrected for randoms, dead time, scatter (Watson, 
2004), attenuation and decay. All frames of the dynamic emission scans were reconstructed 
using filtered back projection and a Hanning filter with a cut-off of 0.5 times the Nyquist 
frequency. In addition, for region of interest (ROI) definition, a summed sinogram from 10 
to 60 min after the start of the scan was reconstructed using an ordered subset expectation-
maximization (OSEM) algorithm with two iterations and 16 subsets. For both 
reconstructions, the full-width at half-maximum of the point spread function was 
approximately 7 mm and the reconstructed voxel size was 1.2 x 1.2 x 2.4 mm. 
 
Kinetic analysis 
 
Areas with visually increased uptake in the synovium were delineated using 50% isocontours 
on the OSEM reconstructed scans. For five patients four to seven areas and for one patient 
two areas with increased uptake were identified. The ROI volumes were between 1.1 and 2.5 
cm3. Time-activity curves (TAC) were created for each ROI. A tracer kinetic model for 
(R)-[11C]PK11195 has been validated for the brain, where the blood-brain barrier prevents 
passage of labeled metabolites into the brain. There is, however, no blood-tissue barrier in 
the knee-cap and it is unknown whether metabolites reach the target region. Therefore, three 
different input functions were generated: (1) the (time-dependent) parent (R)-[11C]PK11195 
concentration in plasma (Cppk), (2) the plasma concentration of parent (R)-[11C]PK11195 and 
its nonpolar metabolites together with (Cppk+np) and (3) the total 11C plasma concentration, 
i.e. (R)-[11C]PK11195 with all its metabolites (Cptotal). These input functions were generated 
in the following way. The plasma/whole blood radioactivity concentration ratio r(t) of the 
discrete blood samples was fitted to an exponential function. The fraction of 
(R)-[11C]PK11195 in plasma of the discrete blood samples was fitted to the function f(t) = a1 
* exp(b1 * t) + (1 - a1) * exp(b2 * t), where f(t) is the fraction of radioactivity in plasma 
originating from (R)-[11C]PK11195 at time t. Cppk was then estimated by multiplying the 
concentration in whole blood by both r(t) and f(t). Cppk+np was obtained in a similar way, 
except that the sum of parent compound and nonpolar metabolites was fitted to the function 
f(t). For Cptotal only a multiplication of the whole-blood concentration by r(t) was required. 
Delay between arrival of the (R)-[11C]PK11195 bolus at the external detector and at the place 
of injection was estimated by fitting a reversible two-tissue compartment model (including a 
delay parameter) to the sum of all ROI in the knee using the appropriate input concentration. 
This (fitted) delay value was then fixed for individual ROIs. 
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Four compartment models were used to fit the ROI data. These were an irreversible one-
tissue model (M1T1K, i.e. one-tissue compartment with one kinetic rate constant), a 
reversible one-tissue model (M1T2K, one-tissue compartment with two kinetic rate 
constants), an irreversible two-tissue model (M2T3K, two-tissue compartments with three 
kinetic rate constants), and a reversible two-tissue model (M2T4K, two-tissue compartments 
with four kinetic rate constants) (Gunn et al., 2001). Variants of these models with and 
without a blood volume (Vb) component were evaluated. If the model contained a correction 
for blood volume, VB was added to the model name, i.e. M1T2KVB instead of M1T2K. For 
the blood volume term, the (total) radioactivity concentration in blood instead of in plasma 
was used. Parameters of interest evaluated were the influx rate constant Ki for M1T2K and 
M2T3K, the volume of distribution (Vd) for M1T2K and M2T4K and additionally a binding 
potential (BP) for M2T4K. For M1T1K, Ki is equal to K1, while it is equal to K1 * k3/(k2 + 
k3) for M2T3K. Vd is defined as K1/k2 for M1T2K and as (K1/k2) * (1 + BP) for M2T4K, 
with BP equal to k3/k4. 
 
For potential use in future clinical applications, where dynamic scanning with arterial blood 
sampling might be problematic, the performance of the standardized uptake value (SUV) was 
also evaluated. SUV is the average radioactivity concentration in an ROI, divided by the total 
injected dose and multiplied by the weight of the subject. It is a semiquantitative measure 
and is commonly used in oncology for the analysis of FDG scans (Westerterp et al., 2006). 
SUV was calculated using the average concentrations between 20 and 40 min, 40 and 60 min 
and 20 and 60 min after injection, respectively. 
 
Due to noise in the data, unrealistic results, such as very high BP or zero Ki, were observed. 
These results were excluded from comparison. For Ki M1T1K and Ki M1T1KVB, all Ki 
values were in the same range and none had to be rejected. For Vd M1T2K, Vd M1T2KVB, 
Vd M2T4K and Vd M2T4KVB, most values of Vd were in the range of 0.5 - 3 and values 
were rejected when Vd was greater than 3. When Ki M2T3K and Ki M2T3KVB were used, 
several Ki values were rejected because they became zero, the lower boundary of the fitting 
algorithm. BP values were rejected when they were greater than 30. To allow a fair 
comparison between different input types, results were rejected for all input types when they 
were rejected for any input type. 
 
The optimal model was selected based on a high preference of the Akaike information 
criterion (AIC, Akaike, 1974), a low number of unrealistic parameter values and ease of data 
acquisition. AIC selects the model with the optimal fit to the data, taking into account the 
number of fitted data points and the number of fitted parameters. When comparing eight 
models at the same time using AIC, it can be hard to identify the optimal model. Therefore 
models with and without blood volume were first compared separately. The optimal model 
was then determined by comparing the optimal models of these comparisons without the 
lower performing models taken into account. The optimal timing for the calculation of the 
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SUV was determined by a high correlation with the optimal compartment model and 
preferably short scan duration. 
 
 
Results 
 
Examples of whole-blood and tissue TAC are shown in figure 1. The ratio of plasma over 
whole-blood concentration was nearly constant over all samples and patients with a value of 
1.55 ± 0.07. It was fitted using a sum of decaying exponents where the number of exponents 
was based on the AIC. Plasma/whole blood concentration ratio fits showed little deviation 
for the measured data. An example is shown in figure 2A. The fraction of radioactivity in 
plasma originating from (R)-[11C]PK11195, measured over all patients, changed from 90 ± 
3% at 3 min to 54 ± 7% at 60 min after injection. Three nonpolar metabolites were observed 
with concentration fractions of 8, 10 and 18% at 60 min after injection. Both the fits to the 
fraction of radioactivity originating from (R)-[11C]PK11195 in plasma and the fits to the 
fraction of radioactivity originating from (R)-[11C]PK11195 and nonpolar metabolites were 
fitted using the function f = 1 - a(2 - exp(-bt) - exp(-ct)), where f is parent fraction and a, b 
and c are positive fitted parameters. The fits showed little deviation from the measured data 
(figure 2B and C). All (dynamic) scans were checked for movement artifacts and for this 
reason two patients were excluded from further analysis. In one patient, SUV could not be 
obtained due to a methodological error and only kinetic modeling was performed. Thus, the 
results from this study are based on the kinetic modeling results from five patients. 
 
The number of parameter values that were rejected because they fell outside the physiological 
range, as defined in the Materials and methods section, varied. The total number of fitted 
TAC was 33. The highest number of rejected values were observed for Ki obtained with 
M2T3KVB (six for Cppk, five for Cppk+np and five for Cptotal, respectively) and for BP obtained 
with M2T4K when Cppk was used as the input function (five). For all other combinations of 
models and input functions, the numbers of rejected values were two or fewer, i.e. 6% or less 
of the total number of fits. 
 
The results of various model comparisons using AIC are shown in table 1, 2 and 3. AIC 
trends were consistent over different input functions. For the models without blood volume 
correction, M2T4K was preferred in most cases, followed by M1T2K. For the models without 
blood volume correction, M2T4K was preferred in most cases, followed by M1T2K. For the 
models with blood volume correction, the order of the one- and two-tissue reversible models 
was reversed. As in both cases a reversible model was optimal, nu further results from 
irreversible compartment models are presented. In general, irreversible models resulted in 
higher numbers of rejected values than reversible models (data not shown). 
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Figure 1. Example of (R)-[11C]PK11195 concentration as a function of time for (A) whole blood and (B) inflamed 
synovium. The curve in B is a fit of a one-tissue reversible model including blood volume using the parent fraction 
as input function.  
 
Figure 2. Example of (A) a plasma/whole-blood radioactivity concentration ratio fit, (B) a plasma parent fraction 
fit and (C) a plasma parent and nonpolar metabolite fraction fit. 
 
When M1T2KVB was compared to M2T4K (table 3), M1T2KVB was preferred in most 
cases for all input functions. A scatter plot of Vd M1T2KVB calculated using Cppk and Cptotal 
is shown in figure 3. Good correlations were observed between Vd M1T2KVB calculated 
with different input functions (R2 = 0.88 between Cppk and Cptotal, R2 = 0.89 between Cppk and 
Cppk+np, and R2 = 1.00 between Cppk+np and Cptotal). 
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Table 1. Number of times a model resulted in the best/second/third/worst fit for the models M1T1K, M1T2K, 
M2T3K and M2T4K according to AIC. The preference of the models was analyzed separately for each input function 
used. 
 
 M1T1K M1T2K M2T3K M2T3K 
     
Cppk 4/2/1/26 7/14/12/0 0/16/16/1 22/1/4/6 
Cppk+np 0/2/3/28 10/9/14/0 0/18/12/3 23/4/4/2 
Cptotal 0/2/3/28 10/9/14/0 0/18/12/3 23/4/4/2 
 
    
 
Table 2.  Number of times a model resulted in the best/second/third/worst fit for the models M1T1KVB, M1T2KVB, 
M2T3KVB and M2T4KVB according to AIC. The preference of the models was analyzed separately for each input 
function used.  
 
     
 M1T1KVB M1T2KVB M2T3KVB M2T4KVB 
    
 
 
Cppk 3/4/1/25 20/6/7/0 4/16/11/2 6/7/14/6 
Cppk+np 0/6/1/26 20/4/9/0 5/15/10/3 8/8/13/4 
Cptotal 0/6/1/26 20/5/8/0 4/16/9/4 9/6/15/3 
 
    
 
Table 3. Number of times a model resulted in the best or worst fit for the models M1T2VB and M2T4K according 
to AIC. The preference of the models was analyzed separately for each input function used. 
 
   
 M1T2VB M2T4K 
   
Cppk 19/14 14/19 
Cppk+np 20/13 13/20 
Cptotal 21/12 12/21 
 
  
 
Scatter plots between Vd M1T2KVB and Vd M2T4KVB and between Vd M1T2K and Vd 
M1T2KVB using either Cppk or Cptotal as input function are shown in figure 4. For most ROI 
one- and two-tissue models provided similar results. This is reflected in the gradients of the 
fitted correlation lines, which were between 0.9 and 1.1 for all input functions. Correlations 
between M1T2KVB and M1T2K were high for all input functions (R2 = 0.91 - 0.96). 
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Figure 3. Scatter plot of Vd M1T2KVB values obtained using Cp
pk and Cp
total as input functions. Different symbols 
represent different subjects. 
 
 
 
Figure 4. Scatter plots between Vd M1T2KVB and Vd M2T4KVB (A, B) and between Vd M1T2K and Vd 
M1T2KVB (C, D) using either Cp
pk (A, C) or Cp
total (B, D) as input function. Different symbols represent different 
subjects.  
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Figure 5. Scatter plot between M1T2KVB using Cp
total as input function and SUV20-40. Different symbols represent 
different subjects. 
 
Average kinetic parameters for M1T2KVB using Cptotal were K1 = 0.03 ± 0.01 mL min-1 mL-1, 
k2 = 0.03 ± 0.01 min-1 and Vb = 0.04 ± 0.04). A high correlation was observed between Vd 
M1T2KVB using Cptotal as input function and SUV20-40 (figure 5, R2 = 0.73). Correlations 
between SUV20-40, SUV20-60 and SUV40-60 were very high (R2 = 0.99 - 1.00). 
 
 
Discussion 
 
In the present study, three different input functions were used: parent (R)-[11C]PK11195 
concentration in plasma (Cppk), sum of parent (R)-[11C]PK11195 and its nonpolar metabolites 
concentrations in plasma (Cppk+np) and total radioactivity concentration in plasma (Cptotal). It 
is likely that all three fractions (i.e. parent, polar and nonpolar metabolite fractions) enter 
tissue, but with different kinetics. It is not possible to select an optimal model based on 
theoretical grounds. From a practical point of view, a model should provide good fits to the 
data and reproducible results. Since the summed fractions of (R)-[11C]PK11195 and its 
nonpolar metabolites from 94 ± 3% at 3 min to 91 ± 3% at 60 min, compared to a constant 
100% fraction for Cptotal, the shape of Cppk+np differed little from that of Cptotal. This is reflected 
in the high correlation (R2 = 1.00) between Vd M1T2KVB using Cppk+np and Cptotal. 
Correlations between Cppk and Cptotal were lower but still high (R2 = 0.88, figure 3). Due to 
the high correlations between Cppk and Cptotal, clinical performance (i.e. sensitivity to change) 
would be similar. Compared with Cppk+np and Cppk, Cptotal has the advantage that no metabolite 
fractions and plasma concentrations need to be measured. Therefore Cptotal was taken as the 
input function of choice. 
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Analysis using AIC indicated that Vd M1T2KVB was the preferred parameter (tables 1, 2 
and 3). Preference for the one-tissue reversible compartment models over the two-tissue 
reversible compartment models is also indicated by the high correlations between these 
models (R2 = 0.82 - 0.92, figure 4A and B), suggesting that little additional information was 
contained within the second compartment. High correlations were also observed between 
results with and without inclusion of Vb (R2 = 0.91 - 0.96, figure 4C and D). Because AIC 
indicated that the model including Vb was optimal, M1T2KVB was selected as the optimal 
model. 
 
Correlation coefficients between different SUV measures were very high (R2 = 0.99 - 1.00) 
and therefore no difference in performance existed between these measures. SUV20-60 had 
lower noise levels than SUV20-40 and SUV40-60 but apparently this did not lead to increased 
performance, probably because the noise level in a 20-min scan is already low (e.g. very good 
correlation between SUV20-40 and SUV40-60). SUV20-60 has the disadvantage of increased risk 
of patient movement, increased patient discomfort and longer occupation of the scanner. 
SUV20-40 performed similarly to SUV40-60 but is slightly more patient friendly. The high 
correlation between Vd M1T2KVB and SUV20-40 (R2 = 0.73, figure 5) indicates that SUV20-40 
is a practical alternative when arterial sampling cannot be performed. 
 
Application of the results to clinical trials is limited by the unknown test-retest variance. 
Knowledge of this variance is relevant in estimating required sample size in clinical studies 
and needs to be assessed in future studies. Three methodological factors may limit the use of 
(R)-[11C]PK11195 as an inflammation marker in the knee. First, results may be influenced 
by physiological (normal) uptake of (R)-[11C]PK11195. In most of the patients, however, 
there was a large difference in the clinical condition of the two knees, and no uptake was 
observed in the knee with no or little inflammation. Furthermore, no uptake in healthy 
controls was observed (data not shown), indicating that high uptake is likely to be related to 
inflammation. Second, uptake of a metabolite that does not bind to the PBR may also 
influence quantification. Although this cannot be ruled out, nonpolar metabolites are 
chemically similar to (R)-[11C]PK11195 and will likely also bind to the receptor. In addition, 
the majority of the radioactivity concentration originates from the parent compound, which 
certainly binds to the receptor. The high correlation between the results obtained with the 
various input functions indicates, however, that the effect of labeled metabolites is small, at 
least in the present patient population. Third, treatment such as disease-modifying 
antirheumatic drugs may influence (R)-[11C]PK11195 metabolism and introduce bias when 
results are compared to those from a normal control group. Future studies are needed to 
investigate the effect of various treatments on (R)-[11C]PK11195 metabolism and thus on 
SUV results. 
 
The kinetics of (R)-[11C]PK11195 and its metabolites in the human knee joint affected by RA 
can best be described by a reversible one-tissue compartment model including a blood 
volume component. There was a good correlation between distribution volume values 
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independent of whether plasma (R)-[11C]PK11195 concentration, plasma (R)-[11C]PK11195 
and nonpolar metabolite concentration or total concentration was used as the input function. 
Based on practical considerations (no metabolite measurements), use of total plasma 
radioactivity concentration is preferred. Because of the good correlation between Vd and 
SUV calculated using the average radioactivity concentration between 20 and 40 min after 
injection, the latter is a practical alternative for routine clinical studies. 
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Summary 
 
The aim of this thesis was to develop methodology to measure neuroinflammation with a 
focus on Alzheimer's disease (AD). In addition, extension of this methodology to rheumatoid 
arthritis was investigated. Inflammation results in expression of the 18 kDa translocator 
protein (TSPO), previously known as the peripheral benzodiazepine or omega-3 receptor. 
(R)-[11C]PK11195 binds to this protein and, therefore, measurements of (R)-[11C]PK11195 
concentrations can be used to quantify inflammation. 
 
In chapter two, a method to quantify neuroinflammation in vivo was developed. Using 
clinical studies and Monte Carlo simulations, the aim of this study was to determine which 
tracer kinetic plasma input model best describes (R)-[11C]PK11195 kinetics. Dynamic 
positron emission tomography (PET) scans were performed on 13 subjects while radio-
activity in arterial blood was monitored online. Discrete blood samples were taken to generate 
a metabolite corrected plasma input function. One-tissue, two-tissue irreversible, and two-
tissue reversible compartment models, with and without fixing K1/k2 ratio, k4 or blood volume 
to whole cortex values, were fitted to the data. The effects of fixing parameters to incorrect 
values were investigated by varying them over a physiologic range and determining accuracy 
and reproducibility of binding potential (BP) and volume of distribution using Monte Carlo 
simulations. Clinical data showed that a two-tissue reversible compartment model was 
optimal for analyzing (R)-[11C]PK11195 PET brain studies. Simulations showed that fixing 
the K1/k2 ratio of this model provided the optimal trade-off between accuracy and 
reproducibility. It was concluded that a two-tissue reversible compartment model with K1/k2 
fixed to whole cortex value is optimal for analyzing (R)-[11C]PK11195 PET brain studies. 
 
The optimal model determined in chapter two is a plasma input model. In practice, a reference 
tissue model is preferred. This requires a brain region without tracer binding. Use of a 
reference tissue model requires validation against a plasma input model as the simpler 
reference tissue models make assumptions on the kinetics of the tracer that are not always 
valid. For instance, the most commonly used model, the simplified reference tissue model 
(SRTM), requires that the free and specifically bound compartments in the time-activity 
curve (TAC) can be merged together. Chapter three determines the optimal reference tissue 
model based on a comparison with the plasma input model from chapter two. Apart from the 
reference tissue models, several mixed models, requiring reference tissue, plasma and whole-
blood TAC as input, were included in the comparison. In order to determine the optimal 
model, correlations between the evaluated model and the plasma input model were 
determined. In addition the influence of various parameters on accuracy and reproducibility 
were evaluated using simulations. Parameters evaluated were the noise level, binding to 
TSPO, binding to different sites and the fraction of the target region that is occupied by blood. 
Results showed optimal correlation for one of the combined models, the plasma-corrected 
simplified reference tissue model (R2 = 0.82) and good results for SRTM (R2 = 0.78). These 
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models also performed well with regard to accuracy and reproducibility. Thus it was 
concluded that the plasma-corrected simplified reference tissue model was optimal when 
reference tissue, plasma and whole-blood TAC are available and SRTM is optimal when only 
reference tissue TAC is available. 
 
As mentioned the use of a reference tissue model requires a region where the receptor of 
interest (in this case the TSPO) is not expressed. In chapter four the optimal reference tissue 
for determining TSPO binding in Alzheimer's disease (AD) was determined. Four subject 
groups (young and old healthy subjects, patients with mild cognitive impairment (MCI), a 
stage preceding AD, and patients with AD) were included in the analysis. The cerebrum, 
cerebellum and a reference tissue determined using a mathematical algorithm called cluster 
analysis, were evaluated as reference tissues. Variants of these regions containing grey 
matter, white matter and the sum of grey and white matter were evaluated. Both the plasma 
input model from chapter two and the reference tissue model from chapter three were used. 
For evaluating the reference tissue region, the thalamus was used as target region, as it has 
increased (R)-[11C]PK11195 binding in elderly subjects and AD patients. In addition, 
simulations were performed to investigate effects of variations in blood volume, noise level 
and BP on cluster analysis reference tissue performance. When evaluating correlations 
between BP values derived using different reference tissue regions, high correlations were 
observed between cluster analysis and both total cerebellum (R2 = 0.76) and grey cerebrum 
(R2 = 0.71) as reference tissues. When evaluating plasma input model BP from the reference 
tissue regions itself, high correlations were observed between plasma input BP using cluster 
analysis compared to anatomical ROI such as the cerebrum (both grey, white and total tissue, 
R2 = 0.93-0.94) and a lower value for the total cerebellum (R2 = 0.69). In addition, simulations 
were performed to determine the performance of cluster analysis to differentiate between 
regions with different BP (2.2 compared to 1.5) and different blood volume (9% compared 
to 6%) at various noise levels (10 and 15% coefficient of variation). Results showed correct 
differentiation between regions with different BP. Blood volume and noise level did not 
significantly influence this differentiation. It was concluded that total cerebellum was the 
optimal reference region with almost similar results obtained for cluster analysis. 
 
In chapter five it was investigated whether increased (R)-[11C]PK11195 binding is present in 
AD and MCI, currently also known as “prodromal AD”. Nineteen patients with probable AD, 
10 patients with prodromal AD, and 21 healthy control subjects were analyzed. These 
subjects were analyzed using receptor parametric mapping (RPM), a parametric 
implementation of SRTM, the optimal reference tissue model as determined in chapter two. 
RPM generates parametric BP images, allowing comparisons between subject groups at the 
voxel level. The reference tissue curve was obtained using cluster analysis evaluated in 
chapter four. Results were analyzed in three different ways. First, statistical differences in 
BP between subject groups were determined at the voxel level using two sample t tests and 
statistical parametric mapping (SPM). Second, differences in BP between anatomical regions 
were determined by using the average BP in the region and testing for statistical differences 
using analysis of covariance. Third, the correlation between BP and several quantitative 
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cognition tests, among others the Mini-Mental State Examination, were evaluated for 
statistical differences. Analysis at the voxel level showed significantly increased BP in the 
occipital lobe of AD patients compared with healthy control subjects. These voxels with 
increased BP, however, were not evenly distributed over the region but occurred in small 
clusters. There were no statistically significant differences in region of interest derived BP 
values between groups. In addition, no correlation between BP and cognition was observed. 
It was concluded that microglial activation is a subtle phenomenon in AD. 
 
In chapter six, a method to quantify inflammation in the knee instead of the brain was 
developed. Data from six patients with rheumatoid arthritis were used. Similar to the 
approach in chapter two for the brain, a kinetic model was developed that quantifies 
(R)-[11C]PK11195 bound to the TSPO protein. The experimental procedure is nearly identical 
to the one for the brain. First, a bolus of (R)-[11C]PK11195 is to be injected into the subject's 
vein. In the following hour, a dynamic PET scan of the knees is performed, while arterial 
blood radioactivity concentration is continuously measured. At set times after injection, 
manual blood samples were taken and used to determine plasma and whole-blood 
concentrations. Plasma TAC assuming either only (R)-[11C]PK11195, (R)-[11C]PK11195 and 
its radioactive polar metabolites or (R)-[11C]PK11195 and all its radioactive metabolites were 
used as input for the plasma input model. Several models, both with and without blood 
volume correction, were evaluated. Again, AIC was used to determine which model best 
described the measured data. As a measure that is more suited for routine clinical use, various 
standard uptake value (SUV) variants were evaluated. SUV is the average radioactivity 
concentration normalized for injected dose and body weight of the subject. AIC indicated 
that the single tissue model with blood volume was the optimal model. This result was 
independent of which of the three plasma input functions were used. In addition, correlations 
between BP values obtained with the various plasma input functions were high. The various 
SUV variants performed nearly identical and correlated well with BP from the optimal 
plasma input model. As all plasma input function provided similar results total plasma could 
be used obviating the need for labor intensive metabolite measurements. In conclusion, the 
optimal plasma input model was the single tissue model with blood volume using total plasma 
activity as input function. As a simpler alternative for routine clinical studies, SUV measured 
between 20 and 40 minutes after (R)-[11C]PK11195 injection could be used. 
 
 
Future perspectives 
 
Two trends have been observed since the publication of the majority of the work in this thesis. 
The first is an ongoing interest in kinetic modeling of (R)-[11C]PK11195 using cluster 
analysis to define the reference tissue input function. The discovery of the vascular 
component in (R)-[11C]PK11195 binding is an important finding in this context (Tomasi et 
al., 2008). The second is the body of new TSPO tracers that are evaluated as an alternative 
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for (R)-[11C]PK11195. For these tracers, genetic differences in binding occur (Owen et al., 
2012). 
 
With regard to the progress in kinetic modeling of (R)-[11C]PK11195, several results are of 
interest. Recently, in case of Alzheimer’s Disease (AD), cluster analysis has become the 
standard for defining the (R)-[11C]PK11195 reference tissue input function. The original 
cluster analysis method, evaluated in chapter four, has been improved resulting in the 
supervised cluster analysis method (Turkheimer et al., 2007). The supervised cluster analysis 
method uses a set of predefined as opposed to a data driven kinetic classes in an attempt to 
improve matching between kinetic classes and underlying physiology, resulting in increased 
accuracy and reproducibility. It has the advantages over anatomically defined regions of 
being observer independent and of automatically removing inflamed regions in the reference 
tissue. It has the disadvantage, however, that for each scanner a separate set of scans is needed 
to define the kinetic classes used. This makes multi-center studies more difficult. The method 
assumes that each TAC is a linear sum of six predefined kinetic classes: grey matter with 
specific binding, grey matter without specific binding, white matter, blood, bone, and soft 
tissue regions. This algorithm segments PET voxels based on differences in TACs. It 
primarily selects reference tissue voxels from grey matter tissue without specific binding 
avoiding binding in blood vessels. This is relevant, as uptake of (R)-[11C]PK11195 to the 
vascular wall was demonstrated, which has implications for modeling and interpretation of 
(R)-[11C]PK11195 data. Results showed good correlation between plasma input and 
reference tissue BP and good test-retest variability. When compared to the original cluster 
analysis method, improved agreement between reference tissue and plasma input models was 
achieved. Application of an MRI derived brain mask to include only brain tissue in the 
clustered voxels was proposed by Boellaard and co-workers (Boellaard et al., 2008) and 
implemented by Yaqub and co-workers (Yaqub et al., 2012). These authors compared a 
manually defined cerebellum, the supervised cluster analysis algorithm mentioned above 
(Turkheimer et al., 2007) and a version of the supervised cluster analysis algorithm that uses 
this MRI based brain mask to exclude non-brain voxels. Data were analyzed using a 
parametric implementation of the simplified reference tissue method (SRTM, Gunn et al., 
1997) and an implementation of SRTM that incorporates a vascular component, SRTMV 
(Tomasi et al., 2008). It was shown that applying the MRI based brain mask resulted in best 
contrast between the subject groups (young controls, elderly controls, subjects suffering from 
MCI and AD patients). The authors suggested that incorporating the vascular component in 
the model results in best performance because the model corrects for the TSPO signal in the 
vessel walls occurring under normal conditions. At present, supervised cluster analysis with 
four predefined clusters (Yaqub et al., 2012) is the most commonly used method to analyze 
(R)-[11C]PK11195 studies. Further studies are needed, however, to facilitate multi-center 
studies. 
 
Analysis of (R)-[11C]PK11195 is hindered by a low signal to noise level. This results in slow 
convergence and the presence of local minima when fitting (R)-[11C]PK11195 TACs. Several 
studies have been performed to improve fitting performance. Anderson (Anderson et al., 
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2007) compared the performance of SRTM, a wavelet-based Logan plot, a basis pursuit 
method, a reference-to-target ratio and a Logan plot. They reported highest sensitivity to 
group differences for the wavelet-based Logan plot, basis pursuit and SRTM. Application of 
functional data from a co-registered MRI using wavelet transforms was applied by 
Turkheimer (Turkheimer et al., 2008). This decreased noise levels of (R)-[11C]PK11195 
scans with approximately 15.5%. Although this technique is not specific for 
(R)-[11C]PK11195 PET scans, it was applied to a (R)-[11C]PK11195 data set, including a 
cluster analysis derived reference tissue input function. Tomasi (Tomasi et al., 2011) applied 
global two stage (GTS) filtering on (R)-[11C]PK11195 scans. GTS is a tracer independent 
and voxel-based method providing binding potential estimates independent of the 
characteristics of the tracer used, assuming preliminary estimates of parameters and their 
covariances are known in advance. GTS, a basis function method (BFM) and weighted 
nonlinear least squares were evaluated. Results for clinical data showed that GTS provided a 
2.3 fold improved sensitivity compared with BFM. Because the high signal to noise ratio is 
still a limiting factor in analysis of (R)-[11C]PK11195, further research on decreasing this 
ratio is needed. 
 
Analysis of (R)-[11C]PK11195 scans is also hampered by the high non-specific signal. 
Because of these methodological limitations, a series of new tracers targeting the TSPO 
receptor, referred to as second generation TSPO tracers, has been evaluated as an alternative 
for (R)-[11C]PK11195. To date, more than 50 tracers have been evaluated, of which 
[11C]DAA1106, [11C]PBR28, [18F]PBR111, [11C]DPA-713, [18F]DPA-714, [18F]FEPPA and 
[11C]vinpocetine are well known examples. Several reviews of these tracers have been 
published (Chauveau et al., 2008, Doorduin et al., 2008, Schweitzer et al., 2010, Rupprecht 
et al., 2010, Taliani et al., 2011).  
 
Most of these TSPO tracers outperform (R)-[11C]PK11195 in laboratory animals. The 
literature evaluating them in humans is limited, however, and so far there is no clear successor 
for (R)-[11C]PK11195, although the number of studies pointing to [11C]PBR28 as a successor 
is increasing. The use of alternative TSPO tracers is complicated by genetically caused 
differences in binding (Owen et al., 2012). Approximately 10% of human subjects scanned 
with [11C]PBR28 did not show binding (Brown et al., 2007, Fujita et al., 2008, Kreisl et al., 
2010). Further studies showed that subjects can be classified as having low, mixed or high 
binding affinity for [11C]PBR28, but also that individual binding classification can be 
determined using a simple genetic test (Owen et al., 2010). This difference in binding affinity 
occurs for all TSPO tracers except (R)-[11C]PK11195, which either does not show any 
difference in binding affinity because it binds to a different site on the TSPO (Owen et al., 
2010) or the difference cannot be measured because of the poor signal to noise ratio. Three 
promising second generation tracers are [11C]PBR28, [18F]PBR111 and [11C]DPA-713. Guo 
and co-workers (Guo et al., 2012) predicted, using a mathematical model based on properties 
such as lipophilicity of a tracer, its free fraction in plasma and in tissue, its affinity for the 
receptor and TSPO receptor density, in vivo performance of these three tracers. They 
concluded that for subjects with mixed or high binding affinity the within-subject variability 
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was significantly lower than for (R)-[11C]PK11195. For between-subject studies, sample 
sizes required to detect 50% differences in TSPO density were approximately half that 
required with (R)-[11C]PK11195 (Guo et al., 2012).  
 
More in vivo human PET studies are required both to confirm this finding and to select the 
optimal TSPO tracer available from the many tracers investigated. It is quite possible that the 
future neuroinflammation tracer of choice binds to a different target than the TSPO receptor, 
as potential binding to the vascular wall may limit the use of all TSPO tracers for 
investigating neuroinflamation (Turkheimer et al., 2007). Alternative inflammation receptors 
being studied are the Somatostatin receptor, the type 2 cannabinoid receptor and the integrin 
receptor. Inhibitors for the cyclooxygenase enzymes COX-1 and COX-2 are also under 
investigation, as well as radiolabeled interleukine-2 and imaging of glucose metabolism, 
choline metabolism, tumor necrosis factor-α, vascular adhesion protein 1 and vascular cell 
adhesion molecule 1. Gallium is being used to quantify vessel permeability, which is thought 
to be linked to inflammation. A recent overview of the work in this field is provided by Wu 
and co-workers (Wu et al., 2013). 
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Achtergrond 
 
Bij een groot aantal ziektes (onder andere Alzheimer en Multiple Sclerose) treedt ontsteking 
op. Dit is een reactie van het lichaam op ongewenste (bijvoorbeeld lichaamsvreemde of 
ziekteverwekkende) stimuli. Ontsteking is een biochemisch proces dat samengaat met een 
geactiveerd immuunsysteem. Een van de gevolgen van ontsteking is dat onderdelen van het 
immuunsysteem (buiten de hersenen witte bloedcellen en in de hersenen microglia) andere 
eigenschappen krijgen. Onder andere komt op de buitenkant van de cellen van het 
immuunsysteem het translocator eiwit beschikbaar. Het in de titel genoemde 
(R)-[11C]PK11195 (verder in dit hoofdstuk 'PK' genoemd) is een stofje dat bindt aan dit eiwit. 
Met andere woorden, het bindt aan een geactiveerd immuunsysteem, oftewel het bindt in 
gebieden waar ontsteking plaats vindt. Daarmee kan het dus gebruikt worden om weer te 
geven welke gebieden ziek zijn in het lichaam. 
 
Doel 
 
PK kan geïnjecteerd worden in de bloedbaan. Zoals gezegd hoopt het zich dan op in zieke 
gebieden van het lichaam. Door hiervoor radioactief gelabeld PK te gebruiken kan de 
verdeling ervan over het lichaam zichtbaar gemaakt worden met een scanner, een 
zogenaamde PET scanner. De scans die door de PET scanner gemaakt worden bevatten 
informatie over de verdeling PK in het lichaam. Echter, deze informatie is te grof om als 
ziektemaat gebruikt te worden. De concentratie van PK in de bloedbaan, de omzetting van 
PK door het lichaam en de snelheid waarmee PK tussen bloed en weefsel getransporteerd 
wordt hebben invloed op deze scans. Doel van dit proefschrift is de vertaling van de ruwe 
scans naar een in een getal uitdrukbare (kwantificeerbare) ziektemaat. Dit kan door een 
modellering (wat zoveel wil zeggen als 'beschrijving') van het transport van PK in het 
menselijk lichaam te maken. Deze modellering beschrijft PK in het lichaam in een aantal 
(conceptuele) compartimenten, waarbij PK in de bloedbaan de oorsprong is van PK van en 
naar de compartimenten. De snelheden waarmee PK getransporteerd wordt tussen de 
compartimenten zijn eigenschappen van het lichaam en bepalen de ziektemaat. Door gemeten 
PK concentraties te koppelen aan compartimentconcentraties kunnen de transportsnelheden 
en daarmee de ziektemaat bepaald worden. 
 
Kwantificering van ontsteking in het brein 
 
Het eerste deel van het onderzoek stelt een model op van het gedrag van PK in de hersenen. 
Hierbij wordt de concentratie in bloedplasma gebruikt om de scandata te vertalen in 
ziektemaat. Voor het bepalen van de ziektemaat wordt zoals gezegd een PET scan gemaakt. 
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Deze PET scan begint met het injecteren van een beetje PK in de bloedbaan in de arm van de 
proefpersoon of patiënt. Via de bloedbaan bereikt het PK vervolgens de hersenen, waar het 
afgebeeld wordt door de PET scanner. Omdat een enkele opname van de hersenen niet 
nauwkeurig genoeg is worden gedurende een uur opnames gemaakt van de hersenen. Er 
wordt dus als het ware een film gemaakt. Tijdens de PET scan wordt continu de concentratie 
PK in de bloedbaan gemeten. Dit geeft informatie over de toevoer van PK naar de hersenen. 
Ook worden er zeven bloedmonsters afgenomen om de omzetting van PK in andere stoffen 
te bepalen. Deze worden gebruikt om de omzetting van PK in en de verwijdering van PK uit 
het lichaam te monitoren. Ook wordt het gebruikt om te bepalen welk deel van de PK in het 
bloed beschikbaar is om naar de compartimenten te stromen. Naast een PET scan wordt er 
ook een MRI scan gemaakt. Hier op is, in tegenstelling tot op een PET scan, de anatomie van 
de hersenen goed zichtbaar. Door de MRI over de PET scan te leggen kan niet alleen in de 
hersenen als geheel maar ook in een specifiek hersengebied bepaald worden hoeveel 
ontsteking er optreedt. 
 
De scans zijn vervolgens geanalyseerd om het model te kiezen dat het gedrag van PK 
optimaal beschrijft. Het kiezen van dit model is een balans vinden tussen een model dat 
enerzijds complex genoeg is om het gedrag van PK realistisch te beschrijven en anderzijds 
simpel genoeg is om met een beperkte hoeveelheid scans bruikbare resultaten te produceren. 
Het is dus zoeken naar een balans tussen realistische beschrijving en praktische 
toepasbaarheid. Een simpel model kan zo sterk afwijken van het daadwerkelijke gedrag van 
PK dat het daardoor consequent onjuiste resultaten geeft. Een complex model geeft 
nauwkeurigere resultaten maar kan een zeer grote hoeveelheid scans nodig hebben voor 
resultaten en daarom praktisch niet toepasbaar zijn. Van drie modellen is gekeken in hoeverre 
ze bij gebruik van PK een bruikbare ziektemaat opleveren. De vergeleken modellen zijn een 
model met een compartiment en twee modellen met twee compartimenten. Het verschil 
tussen de twee modellen met twee compartimenten is dat in het ene model beide 
compartimenten reversibel zijn, terwijl in het andere model een compartiment reversibel is 
en een compartiment irreversibel. Reversibel betekent dat PK dat in het compartiment terecht 
komt dit compartiment ook weer kan verlaten, terwijl in het irreversibele geval dit niet 
mogelijk is. Allereerst zijn daadwerkelijke scans gebruikt om de drie modellen te vergelijken 
met het Akaike informatie criterium ('Akaike'). Dit is een wiskundig criterium dat de balans 
tussen complexiteit en praktische toepasbaarheid vertaalt in een getal. Hier komt uit dat het 
model met twee reversibele compartimenten optimaal is. Naast daadwerkelijke scans zijn 
ook met de computer gesimuleerde (nagebootste) scans gebruikt om het optimale model te 
bepalen. Deze zijn gebruikt om de drie modellen te vergelijken met Akaike en ook hier kwam 
uit dat het model met twee reversibele compartimenten optimaal is. Van dit model zijn 
vervolgens drie varianten vergeleken. Bij deze drie varianten wordt respectievelijk 
verondersteld dat de uitwisseling van PK tussen bloedbaan en weefsel, de volumefractie 
bloedvaten en de mate waarin PK 'plakt' aan het immuunsysteem constant is over het brein. 
Deze varianten zijn onderling weer vergeleken met Akaike, waarbij voor daadwerkelijke data 
uit de scanner het model met constante uitwisseling van PK tussen bloedbaan en weefsel 
optimaal is, terwijl de met de computer gesimuleerde scandata het model met constante 
volumefractie bloedvaten als optimaal aanwijst. Gesimuleerde scans zijn ook gebruikt om 
Nederlandse samenvatting
 
126 
een bewuste 'mismatch' tussen de werkelijkheid en het model te creëren. Hierbij wordt dus 
de uitwisseling van PK tussen bloedbaan en weefsel, dan wel de volumefractie bloedvaten of 
de mate waarin PK 'plakt' aan het immuunsysteem, bewust gevarieerd over het brein, terwijl 
het model er vanuit gaat dat deze variatie er niet is. Gekeken is wat de invloed hiervan is op 
de juistheid van de door het model voorspelde waarden en op de hoeveelheid scans die nodig 
is om bruikbare resultaten te verkrijgen. Hier kwam uit dat voor alle varianten er een beperkte 
mate van onjuistheid in de resultaten geïntroduceerd wordt, maar vooral dat het fixeren van 
de uitwisseling van PK tussen bloedbaan en weefsel zorgt voor een kleinere hoeveelheid 
scans die nodig is om bruikbare resultaten te behalen.  
 
Uit deze verschillende uitkomsten is vervolgens de conclusie getrokken dat het reversibele 
model met twee compartimenten waarbij de uitwisseling van PK tussen bloedbaan en weefsel 
constant verondersteld wordt optimaal is om ontsteking te kwantificeren in de hersenen. 
 
Versimpelde kwantificering van ontsteking in het brein 
 
De hierboven beschreven methode vraagt voortdurende meting van PK concentratie in het 
bloed en een analyse van zeven buisjes bloed. Dit is onaangenaam voor de patiënt of 
proefpersoon, kostbaar en arbeidsintensief. Daarom is onderzocht of er een versimpelde 
kwantificering van ziektemaat in het brein mogelijk is, waarbij niet in de bloedbaan gemeten 
wordt. Bovenstaande methode meet PK concentratie in de bloedbaan en in het zieke 
hersengebied. Simpel gezegd wordt, door deze concentraties met elkaar te vergelijken, de 
ziektemaat bepaald. Als niet in het bloed gemeten wordt is er daarom een andere PK 
concentratie nodig om uit te komen op een ziektemaat. Hiervoor wordt een hersengebied 
waar geen ontsteking/ziekte aanwezig is gebruikt. Door de concentratie PK in het zieke en 
gezonde hersengebied met elkaar te vergelijken wordt de ziektemaat bepaald. Het gezonde 
hersengebied wordt het referentiegebied (referentie weefsel) genoemd. Naast modellen met 
een referentiegebied worden er ook modellen geëvalueerd die zowel PK concentratie in de 
bloedbaan als in een referentiegebied gebruiken. Dit om te kijken of deze modellen beter 
presteren dan modellen met uitsluitend gebruik van PK concentratie in de bloedbaan. 
Er zijn vijf modellen die uitsluitend een referentiegebied en vier modellen die zowel de 
bloedbaan als een referentiegebied gebruiken vergeleken. De modellen zijn geanalyseerd met 
zowel werkelijke als met gesimuleerde scans. Eerst is gekeken naar werkelijke scans. De 
werkelijke scandata is gebruikt om te kijken of de geanalyseerde modellen dezelfde resultaten 
geven als het eerder ontwikkelde model. De drie best presterende modellen hebben resultaten 
die corresponderen met de resultaten van het eerder ontwikkelde model. In de gebieden waar 
het model uit de vorige paragraaf veel ontsteking voorspelt doen deze modellen dat ook. Van 
deze drie modellen gebruikten er twee uitsluitend een referentiegebied en een zowel 
referentiegebied als bloedbaan. De overige zes modellen corresponderen niet sterk genoeg 
met het eerdere model om bruikbaar te zijn. Verder is met gesimuleerde scans gekeken naar 
de invloed van diverse factoren op nauwkeurigheid en benodigde hoeveelheid scans van het 
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model. De invloed van ontsteking, de mate van PK plak buiten het immuunsysteem om en 
fractie bloedvolume zijn geanalyseerd. De modellen die met daadwerkelijke scandata het best 
functioneren deden dat ook met gesimuleerde data. Daar hadden deze modellen relatief 
weinig scans nodig voor bruikbare resultaten. Wel had een van deze drie modellen (een die 
zowel referentiegebied als bloed concentratie gebruikt) de neiging tot onnauwkeurige 
resultaten bij geringe ontsteking. Variatie in PK plak buiten het immuunsysteem en in 
volumefractie bloedvaten had weinig effect.  
 
Een van de modellen die gecombineerd referentiegebied en de bloedbaan als uitgangspunt 
gebruiken (het gecorrigeerd plasma input model) heeft resultaten die goed overeenkomen 
met het hiervoor ontwikkelde model. Van een gecombineerd model wordt in theorie beter 
functioneren verwacht dan van een model met alleen de bloedbaan als uitgangspunt. Daarom 
is geconcludeerd dat dit model optimaal is. Het model dat alleen een referentiegebied 
gebruikt waarvan de resultaten het beste overeenkomen met het eerdere model (het simplified 
reference tissue model) is aangewezen als het optimale model bij gebruik van alleen een 
referentiegebied. 
 
Optimale referentiegebied bij de ziekte van Alzheimer. 
 
Zoals gezegd hebben de versimpelde modellen uit de vorige paragraaf een referentiegebied 
bestaande uit gezond (niet-ontstoken) weefsel nodig. Voortbouwend op het onderzoek in de 
vorige paragraaf is het functioneren van verschillende referentiegebieden gebieden bij de 
ziekte van Alzheimer geanalyseerd. Hiervoor zijn scans gemaakt van drie groepen personen: 
gezonde vrijwilligers, mensen met een voorstadium van de ziekte van Alzheimer en mensen 
met de ziekte van Alzheimer. Als referentiegebieden zijn het cerebellum (een relatief klein 
gebied achter onderaan de hersenen) en het cerebrum (de hersenen zonder het cerebellum) 
gebruikt. Hersengebieden bevatten grijze en witte stof. Zowel het grijze stof gedeelte, het 
witte stof gedeelte als de samenvoeging van de grijze en witte stof gedeeltes (voor het gemak 
'totale stof' genoemd) zijn geanalyseerd als referentiegebied. Daarnaast is de cluster analyse 
als referentiegebied geanalyseerd. De cluster analyse bepaalt gebieden niet op basis van 
anatomische structuren, maar gebruikt de PK concentraties om de hersenen in gebieden met 
verschillende eigenschappen te verdelen. De cluster analyse heeft het voordeel dat het in 
theorie werkt bij hersenen die zo ziek zijn dat er geen anatomisch referentiegebied meer 
aanwijsbaar is. In totaal zijn er zeven referentiegebieden die geanalyseerd zijn: grijze stof 
cerebrum, witte stof cerebrum, totale stof cerebrum, grijze stof cerebellum, witte stof 
cerebellum, totale stof cerebellum en cluster analyse. De referentiegebieden zijn 
geanalyseerd met een model dat gebaseerd is op een referentiegebied. Hierbij werden de 
referentiegebieden geanalyseerd met steeds hetzelfde doelgebied (de thalamus) waarvan 
bekend is dat het verhoogde PK binding heeft. Ook zijn twee modellen die de bloedbaan als 
uitgangspunt gebruikt toegepast om de referentiegebieden te analyseren. Bij toepassen van 
Nederlandse samenvatting
 
128 
deze modellen waren de referentiegebieden zelf het doelgebied. Dit omdat een goed 
referentiegebied weinig ontsteking vertoont. 
 
De ontstekingswaarden gemeten met de cluster analyse en met anatomische gebieden komen 
grotendeels overeen. Voor de referentiegebieden witte stof cerebellum, witte stof cerebrum 
en totale stof cerebrum lukt het de modellen in een aantal gevallen niet een realistische 
ontstekingswaarde te bepalen. Tussen het functioneren van de overige anatomische 
referentiegebieden was weinig verschil. De cluster analyse blijkt het brein goed te scheiden 
in grote bloedvaten, schedel en diverse groepen weefsel met verschillende ontstekingsgraad. 
Om onduidelijke redenen wordt een op de tien breinen niet correct gescheiden door de cluster 
analyse. Bij gebruik van alle drie de modellen correspondeerden de resultaten van de cluster 
goed met die van de best functionerende anatomische gebieden. Daarnaast is met 
gesimuleerde scans gekeken naar het vermogen van de cluster analyse om bloedvaten, 
ontstoken weefsel en niet-ontstoken weefsel (referentiegebied) te scheiden. De cluster 
analyse is hier goed toe in staat. 
 
Uit de groep van goed functionerende anatomische referentiegebieden is bekend dat het 
cerebellum in een laat stadium door de ziekte van Alzheimer aangetast wordt. Daarom is het 
totale stof cerebellum gekozen als best functionerende referentiegebied. De cluster analyse 
is een goed functionerend referentiegebied met de beperking dat deze niet werkt bij ongeveer 
tien procent van de scans. 
 
Ontsteking bij de ziekte van Alzheimer 
 
Het tot nu toe beschreven onderzoek gaat over het ontwikkelen van methoden om ontsteking 
te meten. Deze paragraaf gebruikt deze methoden om het verloop van de ziekte van 
Alzheimer te onderzoeken. Voor dit onderzoek zijn scans gebruikt van gezonde vrijwilligers, 
mensen met een voorstadium van de ziekte van Alzheimer en mensen met de ziekte van 
Alzheimer. Bij deze mensen zijn naast ontsteking in de hersenen door middel van de scan 
ook de cognitieve vaardigheden gemeten. Bij dit onderzoek is het optimale model bij gebruik 
van een referentiegebied, het simplified reference tissue model, gebruikt. Als 
referentiegebied is de cluster analyse gebruikt. Hiermee is, net als in het eerdere onderzoek, 
de ontsteking in anatomische gebieden geanalyseerd. Daarnaast zijn de scans geanalyseerd 
door het model op een parametrische manier toe te passen. Dit betekent dat steeds een heel 
klein volume geanalyseerd wordt met het model. Hierdoor kunnen ook binnen anatomische 
gebieden verhoogde en verlaagde ontsteking geconstateerd worden. Resultaten van de 
analyse met anatomische gebieden tonen geen verschil tussen gezonde vrijwilligers en 
mensen met de ziekte van Alzheimer. Wel werden met de parametrische analyse in de 
occipitale kwab (achterin de hersenen boven het cerebellum) kleine gebieden met verhoogde 
ontsteking gevonden ten opzichte van gezonde vrijwilligers. Er werd geen verband 
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geconstateerd tussen de mate van ontsteking en het cognitief functioneren. Hieruit kan 
geconcludeerd worden dat ontsteking bij de ziekte van Alzheimer een subtiel proces is. 
 
Kwantificering van ontsteking bij reumatoïde artritis 
 
Het laatste deel van het onderzoek is weer een ontwikkeling van de meetmethode zelf. Het 
beschrijft hoe ontsteking bij reumatoïde artritis gemeten kan worden. Van zes patiënten met 
reumatoïde artritis zijn PET scans gemaakt van de knieën. Deze zijn vervolgens geanalyseerd 
en het model dat het nauwkeurigst en tegelijk meest praktisch toepasbaar was is geselecteerd. 
De opzet van dit onderzoek is vergelijkbaar met het eerste deel van het onderzoek bij de 
hersenen.  
Wel is dit onderzoek in een opzicht wat complexer. Gedurende de scan wordt PK namelijk 
door het lichaam omgezet in andere stoffen, ook wel metabolieten genoemd. In de hersenen 
worden deze door de bloed-hersen barrière buiten de hersenen gehouden. In dit onderzoek is 
het onduidelijk of de metabolieten in de knie komen. Hier moet in het model rekening mee 
gehouden worden. Drie situaties zijn meegenomen in deze analyse, namelijk de situatie 
waarbij zowel PK als alle metabolieten in de knie terecht komen, de situatie waarbij PK en 
een gedeelte van de metabolieten (de polaire metabolieten) in de knie terecht komen en de 
situatie waarbij alleen PK in de knie terecht komt. De gebruikte modellen zijn een model met 
een reversibel compartiment, een model met een irreversibel compartiment (waar PK het 
compartiment na eenmaal betreden dus niet meer kan verlaten), een model met twee 
reversibele compartimenten en een model met een reversibel en een irreversibel 
compartiment. Al deze modellen gebruiken de PK concentratie in de bloedbaan als 
uitgangspunt. Van al deze modellen is een variant met en zonder correctie voor volumefractie 
bloedvaten gebruikt. In totaal zijn er dus acht modellen geanalyseerd. Daarnaast is de 
ontsteking gekwantificeerd met de zogenoemde standaard opname waarde (standard uptake 
value of SUV). Dit is een in de kliniek veelgebruikte methode. Waar de modelbeschrijvingen 
van PK het verloop van de PK concentratie in de tijd (als in een film) als invoer nodig hebben 
heeft de SUV slechts de gemiddelde PK concentratie over een periode nodig. Dit maakt de 
scanprocedure veel eenvoudiger. 
 
Bij het analyseren van de resultaten bleek dat, net als bij het bepalen van het optimale 
referentiegebied bij de ziekte van Alzheimer, sommige modellen het niet lukte om in een 
aantal gevallen een realistische ontstekingswaarde te bepalen. Dit waren het model met een 
reversibel en een irreversibel compartiment met correctie voor volumefractie bloedvaten en 
het model met twee reversibele compartimenten zonder correctie voor volumefractie 
bloedvaten. Verder zijn de modellen geanalyseerd met het eerder beschreven Akaike 
criterium. Het Akaike criterium beschouwt het model met een reversibel compartiment en 
correctie voor volumefractie bloedvaten en het model met twee reversibele compartimenten 
zonder correctie voor volumefractie bloedvaten optimaal. Een gedeelte van de gemeten PK 
concentratie in de knieën is dus te beschrijven als PK dat zich in een bloedvat bevindt of als 
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PK dat zich in een compartiment bevindt. Bij onderling vergelijken van deze twee modellen 
geeft Akaike de voorkeur aan het model met een reversibel compartiment en correctie voor 
volumefractie bloedvaten. Verder is gekeken hoe, voor de best presterende modellen, het 
gedrag van de metabolieten van invloed is. Hieruit bleek dat er weinig verschil zat in 
resultaten, onafhankelijk van het gedrag van de metabolieten. De resultaten van de 
verschillende reversibele modellen bleken grotendeels hetzelfde, onafhankelijk van de 
compartimenten. Ook correctie voor volumefractie bloedvaten bleek weinig invloed te 
hebben op de resultaten. Er was een duidelijke relatie tussen de resultaten van het volgens 
Akaike beste model, het model met een reversibel compartiment en correctie voor 
volumefractie bloedvaten, en de SUV. 
 
Uit bovenstaande resultaten is geconcludeerd dat het model met een reversibel compartiment 
en correctie voor volumefractie bloedvaten optimaal is voor het kwantificeren van ontsteking 
bij reumatoïde artritis. Bij voorkeur wordt er bij toepassen van dit model uitgegaan van de 
situatie waarbij zowel PK als alle metabolieten in de knie terecht komen. Andere metaboliet 
situaties geven hetzelfde resultaat maar hebben een complexere scanprocedure. De SUV is 
echter de meetmethode van voorkeur bij reumatoïde artritis. Dit omdat deze meetmethode in 
de praktijk eenvoudig en goedkoop is, en de beperkt mindere resultaten in vergelijking met 
het toepassen van een model hier niet tegen op wegen. 
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